ПРИМЕНЕНИЕ ИОННЫХ ЖИДКОСТЕЙ С АНИОНАМИ ТЕТРАЦИАНОБОРАТА В КАЧЕСТВЕ РАСТВОРИТЕЛЯ ДЛЯ ЭКСТРАКЦИИ СПИРТОВ ИЗ ВОДНЫХ РАСТВОРОВ

1. Способ жидкостно-жидкостной экстракции спиртов из водных растворов с применением, по меньшей мере, одной ионной жидкости, содержащей анионы тетрацианобората в качестве растворителя. ! 2. Способ по п.1, отличающийся тем, что ионная жидкость, содержащая анионы тетрацианобората, с водным раствором, содержащим, по меньшей мере, один спирт, образует, по меньшей мере, одну двухфазную смесь. ! 3. Способ по п.1 или 2, причем ! a) приготавливают водный раствор, содержащий, по меньшей мере, один спирт, ! b) водный раствор из а) интенсивно смешивают с, по меньшей мере, одной ионной жидкостью, содержащей ионную жидкость, которая содержит анионы тетрацианобората, так что ионная жидкость в состоянии, экстрагировать, по меньшей мере, одну часть спирта из водного раствора и с этим спиртом получить одну, по меньшей мере, однофазную смесь, ! c) отделяют, по меньшей мере, однофазную смесь из b) от водного раствора, ! d) разделяют однофазную смесь из b) на компоненты спирт и ионная жидкость, и при необходимости ! e) возвращают ионную жидкость из d) в стадию b). ! 4. Способ по п.1 или 2, отличающийся тем, что способ осуществляют непрерывно или полунепрерывно. ! 5. Способ по п.1 или 2, отличающийся тем, что, по меньшей мере, один спирт выбран из группы этанол, изопропанол, пропанол, n-бутанол или изомеров n-бутанола или их смесей. ! 6. Способ по п.5, отличающийся тем, что, по меньшей мере, один спирт представляет собой n-бутанол. ! 7. Способ по п.1 или 2, отличающийся тем, что водный раствор, содержащий, по меньшей мере, один спирт представляет собой ферментационный бульон. ! 8. Способ по п.1 или 2, отличающийся тем, что ферментационный бульон получают из ацетонбутанолэтанолфе� РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2010 152 751 (13) A (51) МПК C07D 213/20 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (71) Заявитель(и): МЕРК ПАТЕНТ ГМБХ (DE) (21)(22) Заявка: 2010152751/04, 15.05.2009 Приоритет(ы): (30) Конвенционный приоритет: 26.05.2008 EP ...

СПОСОБ ПОЛУЧЕНИЯ ОНИЕВЫХ СОЛЕЙ С ТЕТРАФТОРБОРАТНЫМ АНИОНОМ, ИМЕЮЩИХ НИЗКОЕ СОДЕРЖАНИЕ ГАЛОГЕНИДОВ

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß RU (19) (11) 2007 126 760 (13) A (51) ÌÏÊ C07D 233/58 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2007126760/04, 18.11.2005 (71) Çà âèòåëü(è): ÌÅÐÊ ÏÀÒÅÍÒ ÃÌÁÕ (DE) (30) Êîíâåíöèîííûé ïðèîðèòåò: 14.12.2004 DE 102004060073.2 27.07.2005 DE 102005035103.4 (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 16.07.2007 (87) Ïóáëèêàöè PCT: WO 2006/063653 (22.06.2006) R U (54) ÑÏÎÑÎÁ ÏÎËÓ×ÅÍÈß ÎÍÈÅÂÛÕ ÑÎËÅÉ Ñ ÒÅÒÐÀÔÒÎÐÁÎÐÀÒÍÛÌ ÀÍÈÎÍÎÌ, ÈÌÅÞÙÈÕ ÍÈÇÊÎÅ ÑÎÄÅÐÆÀÍÈÅ ÃÀËÎÃÅÍÈÄΠ(57) Ôîðìóëà èçîáðåòåíè 1. Ñïîñîá ïîëó÷åíè îíèåâûõ òåòðàôòîðáîðàòîâ ïóòåì ââåäåíè â ðåàêöèþ îíèåâîãî ãàëîãåíèäà ñ òðèàëêèëîêñîíèé òåòðàôòîðáîðàòîì, òðèàëêèëñóëüôîíèé òåòðàôòîðáîðàòîì èëè òðèôåíèëêàðáîíèé òåòðàôòîðáîðàòîì. 2. Ñïîñîá ïî ï.1, îòëè÷àþùèéñ òåì, ÷òî ãàëîãåíèä â ñëó÷àå ðåàêöèè ñ òðèàëêèëîêñîíèé òåòðàôòîðáîðàòîì èëè òðèôåíèëêàðáîíèé òåòðàôòîðáîðàòîì ïðåäñòàâë åò ñîáîé ôîñôîíèé ãàëîãåíèä, òèîóðîíèé ãàëîãåíèä, ãóàíèäèíèé ãàëîãåíèä èëè ãàëîãåíèä ñ ãåòåðîöèêëè÷åñêèì êàòèîíîì, èëè â ñëó÷àå ðåàêöèè ñ òðèàëêèëñóëüôîíèé òåòðàôòîðáîðàòîì ïðåäñòàâë åò ñîáîé àììîíèé ãàëîãåíèä, ôîñôîíèé ãàëîãåíèä, òèîóðîíèé ãàëîãåíèä, ãóàíèäèíèé ãàëîãåíèä èëè ãàëîãåíèä ñ ãåòåðîöèêëè÷åñêèì êàòèîíîì. 3. Ñïîñîá ïî ï.1, îòëè÷àþùèéñ òåì, ÷òî ãàëîãåíèä ñîîòâåòñòâóåò ôîðìóëå (1) , ãäå Õ ïðåäñòàâë åò ñîáîé N, Ð; Hal ïðåäñòàâë åò ñîáîé Cl, Br èëè I; è R â êàæäîì ñëó÷àå, íåçàâèñèìî îäèí îò äðóãîãî, ïðåäñòàâë åò ñîáîé Í, ãäå âñå çàìåñòèòåëè R íå ìîãóò îäíîâðåìåííî ïðåäñòàâë òü ñîáîé Í, ëèíåéíûé èëè ðàçâåòâëåííûé àëêèë, êîòîðûé èìååò 1-20 Ñ àòîìîâ, ëèíåéíûé èëè ðàçâåòâëåííûé àëêåíèë, êîòîðûé èìååò 2-20 Ñ àòîìîâ è îäíó èëè áîëåå äâîéíûõ ñâ çåé, ëèíåéíûé èëè ðàçâåòâëåííûé àëêèíèë, êîòîðûé èìååò 2-20 Ñ àòîìîâ è îäíó èëè áîëåå òðîéíûõ ñâ çåé, Ñòðàíèöà: 1 RU A 2 0 0 7 1 2 6 7 6 0 A Àäðåñ äë ïåðåïèñêè: 101000, Ìîñêâà, Ì.Çëàòîóñòèíñêèé ïåð., 10, êâ.15, "ÅÂÐÎÌÀÐÊÏÀÒ", ïàò.ïîâ. È.À.Âåñåëèöêîé 2 0 0 7 1 2 6 7 6 0 (86) Çà âêà PCT: EP ...

PFLANZENWACHSTUMSREGULATOREN ENTHALTENDE ZUSAMMENSETZUNGEN

Verfahren zur Herstellung von Onium-Salzen mit Alkyl- oder Arylsulfonat-Anionen oder Alkyl- oder Arylcarboxylat-Anionen mit geringem Halogenid-Gehalt

Die Erfindung betrifft ein Verfahren zur Herstellung von Onium-Salzen mit Alkyl- oder Arylsulfonat-Anionen oder Alkyl- oder Arylcarboxylat-Anionen durch Umsetzung eines Onium-Halogenids mit einem Alkyl- oder Trialkylsilylester einer Alkyl- oder Arylsulfonsäure oder einer Alkyl- oder Arylcarbonsäure oder deren Anhydride.

Quarternaere 3-Phenyl-3-cyclohexen-(1')-yl-propyl-(1)-N-methylpperidiniumsalze und Verfahren zu ihrer Herstellung

Compositions and methods

Improvements in or relating to the manufacture of quaternary ammonium salts

Saturated heterocyclic bases such as piperidine are reacted with alkyl chlorides containing at least eight carbon atoms, and the N-alkyl derivatives so obtained are converted into quaternary ammonium salts by reaction with an alkylating agent which introduces an alkyl radicle of not more than six carbon atoms. In an example, piperidine is heated with cetyl chloride and the product is treated with dimethyl sulphate; the cetylmethylpiperidinium methyl sulphate so obtained is useful in making aqueous emulsions of paraffin, cetyl alcohol, olive oil and like materials, and the emulsions may then be used, as such or after addition of sodium carbonate, for the treatment of fibrous materials. The emulsions are stated to be more easily absorbed by the fibrous materials than emulsions prepared with the aid of quaternary ammonium salts derived from cyclic tertiary bases of the pyridine type. The Specification also refers by way of comparison to processes in which salts or quaternary salts of higher ...

Compositions and methods

Method for producing substituted 5-fluoro-1H-pyrazolopyridines

Method for producing substituted 5-fluoro-1H-pyrazolopyridines

Method for producing substituted 5-fluoro-1H-pyrazolopyridines

Method for producing substituted 5-fluoro-1H-pyrazolopyridines

Method for producing substituted 5-fluoro-1H-pyrazolopyridines

MITTEL ZUR REGULATION DES PFLANZENWACHSTUMS

PROCEDURE FOR THE PRODUCTION OF NEW OF QUATERNAERER AMMONIUM SALTS OF PHENYLPROPYLAMINEN AND PHENYLBUTYLAMINEN

VERFAHREN ZUR HERSTELLUNG NEUER QUATERNAERER AMMONIUMSALZE VON PHENYLPROPYLAMINEN UND PHENYLBUTYLAMINEN

PROCEDURE FOR THE PRODUCTION OF PERFLUORALKANSULFONSÄUREESTERN

PROCEDURE FOR THE PRODUCTION OF ONIUM ALKYL SULFATES WITH SMALL HALIDE CONTENT

CHINUCLIDINOL DERIVATIVES AS MUSCARINREZEPTORANTAGONISTEN

PROCEDURE FOR THE PRODUCTION OF NEW OF QUATERNAERER AMMONIUM SALTS OF PHENYLPROPYLAMINEN AND PHENYLBUTYLAMINEN

PROCEDURE FOR THE PRODUCTION OF PERFLUORALKANSULFONSÄUREESTERN AND THEIR SALTS

MEANS FOR THE REGULARIZATION OF PLANT GROWTH

MEANS FOR THE REGULARIZATION OF PLANT GROWTH

IONI LIQUIDS, YOUR PRODUCTION AND YOUR USE

Procedure for the production of new quarternären 3-Phenyl-3-cyclohexen (1 ') - yl-propyl (1) - N-methyl-piperidiniumsalzen

Thermal- and photoinitiated radical polymerization in the presence of an addition fragmentation agent

Nicotinic receptor agonists for the treatment of inflammatory diseases

Synthesis of hetero ionic compounds using dialkylcarbonate quaternization

Methods of preparing hetero ionic complexes, and ionic liquids from bisulfate salts of heteroatomic compounds using dialkylcarbonates as a primary quaternizing reactant are disclosed. Also disclosed are methods of making electrochemical cells comprising the ionic liquids, and an electrochemical cell comprising an alkaline electrolyte and a hetero ionic complex additive.

EMULSIONS

QUATERNARY AMINE CONTAINING ETHER OR ESTER LIPID DERIVATIVES AND THERAPEUTIC COMPOSITIONS

METHOD FOR PRODUCING PERFLUOROALKANE SULFONIC ACID ESTERS AND THE SALTS THEREOF

The invention relates to a method for producing perfluoroalkane sulfonic acid esters and their subsequent conversion into salts, in addition to the use of the produced compounds in electrolytes and batteries, capacitors, supercapacitors and galvanic cells.

METHODS FOR EXTRACTION, PROCESSING, AND PURIFICATION OF A SELECTED FAMILY OF TARGET COMPOUNDS FROM CANNABIS

Disclosed are methods for separating, recovering, and purifying tetrahydrocannabinolic acid (THCA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in a selected C5-C7 hydrocarbon solvent, adding thereto a selected amine to thereby precipitate a THCA-amine salt therefrom, dissolving the recovered THCA-amine salt in a selected solvent and then adding thereto a selected antisolvent to thereby recrystallize a purified THCA-amine salt therefrom. The recrystallized THCA-amine salt may be decarboxylated to form a mixture of A9-tetrahydrocannabinol (A9-THC) and amine. The A9-THC amine mixture may be acidified to separate the amine from A9-THC. The recovered A9-THC may be concentrated to produce a highly purified A9-THC. Also disclosed are THCA-amine salts produced with amines selected from groups of diamines, amino alcohols, and tertiary amines.

METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES

The present application relates to a novel and efficient process for preparing novel substituted -fluoro-1H-pyrazolopyridines of the formula (VI) (see formula IV) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) (see formula I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.

SUBSTITUTED OCTYL-PIPERIDINIUM CHLORIDES, BROMIDES OR IODIDES

PLANT GROWTH REGULATOR COMPOSITIONS

The invention provides novel mepiquat plant growth regulator compositions which have improved hygroscopicity and corrosion characteristics. The novel mepiquat plant growth regulator compositions of the invention can be readily prepared from technical mepiquat chlorid inter alia by electrochemical ion exchange processes or by quaternization of N-methylpiperidine with dimethylcarbonate as starting material.

EMM-23 MOLECULAR SIEVE MATERIAL, ITS SYNTHESIS AND USE

A new molecular sieve material is designated as EMM-23 and has, in its as-calcined form, an X-ray diffraction pattern including the following peaks in Table 1 : ...

SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES

A method of synthesizing a crystalline molecular sieve having an MSE framework type comprises crystallizing a reaction mixture comprising a source of water, a source of an oxide of a tetravalent element, Y, selected from at least one of silicon, tin, titanium, vanadium, and germanium, optionally a source of a trivalent element, X, a source of an alkali or alkaline earth metal, M, and a source of organic dications, Q, such as 3 -hydroxy-1-(4-(l -methylpiperidiii-1-ium-1- yl)butyl)quinuclidin-1-ium, 3-hydroxy-1-(5 -(1-methylpiperidin-1-ium-1-yl)pentyl)quinuclidin-1-ium,1, 1 '-(butane-1,4-diyi)bis(1 -methylpiperidin-1-ium), 1, 1 '-(pentane- 1,5-diyi)bis(1 -methylpiperidin-1-ium), 1, 1 '-(hexane-1,6-diyl)bis( 1 - metbylpiperidm-l -ium), and/or l,r-((3as,6a,9)-octahydropentalene-2,5-diyl)bis(l- methylpiperidm-1-ium).

USE OF AN IONIC LIQUID FOR STORING HYDROGEN

Method of storing hydrogen by forming a first ionic liquid by inducing a borohydride in a second ionic liquid comprising a cation and an anion comprising borate, and forming the second ionic liquid by releasing the hydrogen out of the first ionic liquid by using water and/or a catalyst, which method is characterized in that the first and the second ionic liquid are both water miscible and the second ionic liquid is separated, particularly is salted out, from solution in water by adding a separation inducer; certain ionic liquids for storing and releasing hydrogen comprising a borohydride or for preparing a ionic liquid for storing and releasing hydrogen comprising a borate; and a process for preparing ionic liquids for storing and releasing hydrogen comprising a borohydride.

Verfahren zur Herstellung eines wasserlöslichen, höhermolekularen, a-substituierten Benzylaminderivates.

Verfahren zur Herstellung eines wasserlöslichen, höhermolekularen, a-substituierten Benzylaminderivates.

Verfahren zur Herstellung von neuen quaternären Piperaziniumverbindungen

Procédé de préparation de sels d'ammonium quaternaires

Lagerung für die senkrechte Welle eines Messgerätes, insbesondere eines Induktions-Elektrizitätszählers

Verfahren zur Herstellung von quarternären 3-Phenyl-3-cyclohexen-(1')-yl-propyl-(1)-N-methyl-piperidiniumsalzen

Mittel zur Hemmung des Pflanzenwachstums und zur Änderung des Pflanzenhabitus

Verfahren zur Herstellung von neuen quaternären Piperaziniumverbindungen

Verfahren zur Herstellung von neuen Piperazinen

Methyl hydroxypentyl delta-cyclohexene carbaldehyde prepn. - by hydrating dimorpholino-methyl-masked aminals and removing dimorpholino gp.

Delta3-Cyclohexene carbaldehydes of formula (I): (where formyl gp. is in posn. 4 or 5), and mixts. of the 4- and 5- posn. isomers (I), are prepd. by hydrating an animal of formula (II).

QUATERNARY AMMONIUM DERIVATIVES FOR THERAPEUTIC ACTIVITY.

SALICYLATES IS LIPOPHILIC QUATERNARY AMMONIUM COMPOUNDS, THEIR USE IN COSMETICS AND DERMOPHARMACY.

USE OF ION LIQUID STI FOR STORAGE OF HYDROGEN

METHOD OF PREPARING SUBSTITUTED 5-FLUORINE-1H-AND-THE PYRAZOLEPYRIDINES

METHOD OF OBTAINING THE QUATERNARY AMMONIUM CONNECTIONS

METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES

Corrosion inhibitor for clean diverting acid, and preparation method thereof

Use of ionic liquids with tetracyanoborate anions as a solvent for extraction of alcohols from aqueous solutions

本发明的主题是使用至少一种包含四氰基硼酸根阴离子的离子液体作为溶剂，从水溶液中液-液萃取醇的方法。

Production of new quaternary nitrogenized combinations

ELECTROLYTE FORMULATIONS

REACTIVE IONIC LIQUIDS

Composto, composição farmacêutica, e, métodos para tratar ou previnir câncer, degeneração macular de tipo úmido ou artrite reumatóide, vascularização anÈmala, nìveis de cobre em excesso em um paciente, obesidade e doença neurodegenerativa em um paciente

COMPOSICOES REGULADORAS DO CRESCIMENTO VEGETAL,E,PROCESSO PARA PREPARACAO DE SAIS DE FENILPROPIL-AMONIO NELAS APLICAVEIS

NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

L'invention se rapporte à l'utilisation d'agonistes ou d'analogues du récepteur de nicotine ou des dérivés de celui-ci dans le traitement de maladies pulmonaires inflammatoires. Cette invention porte aussi sur des compositions pharmaceutiques contenant des agonistes ou des analogues du récepteur de nicotine ou des dérivés de celui-ci. Elle concerne également des nouveaux composés de la formule I dans laquelle R1, R2, Xa et Ya sont tels que définis ci-après.

PLANT GROWTH REGULATOR COMPOSITIONS

The invention provides novel mepiquat plant growth regulator compositions which have improved hygroscopicity and corrosion characteristics. The novel mepiquat plant growth regulator compositions of the invention can be readily prepared from technical mepiquat chlorid inter alia by electrochemical ion exchange processes or by quaternization of N-methylpiperidine with dimethylcarbonate as starting material.

Monomeric emulsion stabilizers

A novel class of monomeric emulsion stabilizers consists of certain types of ethylenically unsaturated radicals covalently linked to a quaternary nitrogen atom which in turn is covalently linked to a lipophilic radical. Such monomers will polymerize with other ethylenically unsaturated radicals forming self-stabilized, surfactant-free polymeric dispersions.

FLUORIDE ION BATTERY ELECTROLYTE COMPOSITIONS

A fluoride ion battery includes a substantially lithium-free anode and cathode. At least one of the anode or cathode contains fluorine, and a substantially lithium-free liquid electrolyte is used for charge transport. The electrolyte is liquid at temperatures below about 200 degrees Celsius, and can be formed from an organic-soluble fluoride salt dissolved in selected classes of solvents. 1. An electrolyte comprising an organic-soluble fluoride salt containing at least one of alkylammonium or substituted alkyl ammonium cations RRRRNF , where R , R , Rand Rmay each be separately a substituted or unsubstituted , linear or branched , Cto Caliphatic or cyclic aliphatic , fluoroalkyl , oligo(ethyleneglycol) , aryl or substituted aryl group.235.-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/285,903, filed Dec. 11, 2009, the disclosure of which is incorporated by reference herein.The present invention relates to non-aqueous electrochemical cells based on fluoride ion transfer, suitable liquid electrolyte compositions containing fluoride ion salts, and to their use in electrochemical cells, including batteries, capacitors, supercapacitors, and galvanic cells.A battery generally includes a positive electrode (cathode during discharge), a negative electrode (anode during discharge) and an electrolyte for ion transport. The electrolyte can contain one or more ionic species that that act as charge carriers. Many widely available battery systems are based on cation electrode reactions, with electrodes capturing or releasing a cation from an electrolyte and balancing the charge with an electron from the external circuit. Because of its very low electrochemical oxidation/reduction potential and light weight, the element lithium is commonly used in cation based battery systems. Both lithium and lithium-ion batteries are commercially available and widely used.However, the electrochemistry of lithium metal or lithium containing electrodes ...

QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

The invention provides compounds of formula (I) wherein R5 is a group of formula (II) or (III) and R1, R2, R3, R4, R6, a, b, Z, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.

Mepiquat chloride

СПОСОБ ПОЛУЧЕНИЯ ОНИЕВЫХ СОЛЕЙ С ТЕТРАФТОРБОРАТНЫМ АНИОНОМ, ИМЕЮЩИХ НИЗКОЕ СОДЕРЖАНИЕ ГАЛОГЕНИДОВ

Изобретение относится к новому улучшенному способу получения ониевых тетрафторборатов путем введения в реакцию ониевого галогенида с триалкилоксоний тетрафторборатом, триалкилсульфоний тетрафторборатом или трифенилкарбоний тетрафторборатом, отличающемуся тем, что галогенид соответствует формуле (1) ! ! где X представляет собой N, Р, Hal представляет собой Сl, Вr или I и R в каждом случае, независимо один от другого, представляет собой линейный алкил, который имеет 1-8 С атомов, или галогенид соответствует формуле (2) ! ! где Hal представляет собой Вr или I и R1-R7 каждый, независимо один от другого, представляет собой линейный алкил, который имеет 1-8 С атомов, или галогенид соответствует формуле (3) ! ! где Hal представляет собой Сl, Вr или I и R1-R6 каждый, независимо один от другого, представляет собой линейный алкил, который имеет 1-8 С атомов, или галогенид соответствует формуле (4) ! ! где Hal представляет собой Сl, Вr или I и HetN+ представляет собой гетероциклический катион, выбранный ...

СПОСОБ ПОЛУЧЕНИЯ СТРУКТУРИРОВАННОГО СТРУКТУРООБРАЗУЮЩЕГО АГЕНТА

Предложен способ получения структурообразущего агента (SDA) для синтеза кристаллических молекулярных сит, включающий стадии: a. гидролиза алкилсульфатного противоиона четвертичной аммониевой соли, с получением органической аммониевой соли, содержащей гидросульфатный противоион; и b. контактирования органической аммониевой соли, содержащей гидросульфатный противоион, с источником гидроксида в растворе, с образованием органической аммониевой соли, содержащей гидроксидный противоион; где четвертичная аммониевая соль включает аммониевый ион, выбираемый из N,N-диметил-3,5-диметилпиперидиния; N,N-диэтил-2,6-диметилпиперидиния; N,N-диметил-2,6-диметилпиперидиния; N-этил-N-метил-2,6-диметилпиперидиния; N,N-диэтил-2-этилпиперидиния; N,N-диметил-2-этилпиперидиния; N-этил-N-метил-2-этилпиперидиния; и N-этил-N-пропил-2,6-диметилпиперидиния, и где органическая аммониевая соль представляет собой структурообразущий агент (SDA) для синтеза кристаллических молекулярных сит. Технический результат: разработан ...

МОЛЕКУЛЯРНОЕ СИТО EMM-23, ЕГО СИНТЕЗ И ПРИМЕНЕНИЕ

... 1. Молекулярное сито, в прокаленной форме обладающее рентгенограммой, включающей следующие пики, указанные в таблице 1:2. Сито по п. 1, обладающее составом, представленным в виде молярного отношенияXO:(n)YO,в котором n равно не менее примерно 10, Х обозначает трехвалентный элемент и Y обозначает четырехвалентный элемент.3. Сито по п. 2, в котором Х включает один или большее количество из следующих: В, Al, Fe и Ga, и Y включает один или большее количество из следующих: Si, Ge, Sn, Ti и Zr.4. Сито по п. 2, в котором Х включает алюминий и Y включает кремний и/или германий.5. Молекулярное сито, обладающее в синтезированном виде рентгенограммой, включающей следующие пики, указанные в таблице 2:6. Сито по п. 5, обладающее составом, представленным в виде молярного отношения:kF:mQ:XO:(n)YO,в котором 0≤k≤0,2, 0 Подробнее

Способ получения производных фенилалкиламина

QUATERNÄRE AMMONIUMPHOSPHAT-VERBINDUNGEN UND VERFAHREN ZU DEREN HERSTELLUNG

QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION

QUATERNARY AMMONIOM SALTS AND THEIR FORMULATIONS USE AND PREPARATION

Improvements in the production of quaternary ammonium salts

Quaternary ammonium carbonates and formates are obtained by heating carbonic or formic esters with tertiary amines in which the nitrogen atom does not form part of a ring of aromatic character. The reaction is preferably carried out under pressure at 120-250 DEG C.; a solvent or diluent may be present. Examples show the production of (1) tetramethylammonium formate from trimethylamine and methyl formate; (2) hexane - 1 : 6 - bis - (trimethylammonium carbonate) from 1 : 6 - bis - dimethylamino - hexane and dimethyl carbonate; (3) choline carbonate from trimethylamine and glycol carbonate; and (4) 3-methylpentane-1 : 5-bis-(N-methylpyrrolidinium) carbonate from 3-methyl - 1 : 5 - dipyrrolidino - pentane and dimethyl carbonate. The carbonate salts (2)-(4) may be converted to salts of other inorganic or organic acids, the tartrates being exemplified. Other specified amines are triethylamine, dimethylethanolamine, diethylisopropylamine, dimethyloleylamine, N : N - diethylcyclohexylamine, dimethylaniline ...

Means for the inhibition of plant growth and for the change of the Pflanzenhabitus

PROCEDURE FOR THE PRODUCTION OF ONIUM SALTS WITH TETRAFLUOROBORAT ANION WITH REDUCED HALIDE CONTENT

PROCEDURE FOR THE PRODUCTION OF ONIUMALKYLSULFONATEN

IMAGING MATERIAL AND AMMONIUM COMPOUND

DERIVATIVES OF FLUORINE CARBONIC ACIDS, YOUR PRODUCTION AND USE AS PLANT GROWTH MODULATORS.

A method of growing cotton

METHODS FOR EXTRACTION, PROCESSING, AND PURIFICATION OF A SELECTED FAMILY OF TARGET COMPOUNDS FROM CANNABIS

Disclosed are methods for separating, recovering, and purifying cannabidiolic acid (CBDA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in C5-C7 hydrocarbon solvents, adding thereto a selected amine to thereby precipitate a CBDA-amine salt therefrom, dissolving the recovered CBDA-amine salt in a selected solvent and then adding thereto a selected antisolvent to thereby recrystallizing a purified CBDA-amine salt therefrom. The recrystallized CBDA-amine salt may be decarboxylated to form a mixture of cannabidiol (CBD) and amine. The CBD amine mixture may be acidified to separate the amine from CBD. The recovered CBD may be concentrated to produce a highly purified CBD. Also disclosed are CBDA-amine salts produced with certain amines selected from groups of secondary amines, tertiary amines, diamines, amino alcohols, amino ethers, and highly basic amines.

EMM-23 MOLECULAR SIEVE MATERIAL, ITS SYNTHESIS AND USE

A new molecular sieve material is designated as EMM-23 and has, in its as-calcined form, an X-ray diffraction pattern including the following peaks in Table 1 : ...

ANALOGS OF TIOMOLIBDATA AND THEIR APPLICATION

Composed of piperazine and their preparation

DERIVED From AMMONIUM QUATERNARY HAS THERAPEUTIC ACTIVITY

NEW LIPOPHILIC QUATERNARY AMMONIUM SALICYLATES, THEIR USE IN COSMETIC AND DERMOPHARMACIE

SALICYLATE LIPOPHILE D'AMMONIUM QUATERNAIRE, CARACTERISE PAR LE FAIT QU'IL REPOND A LA FORMULE : (CF DESSIN DANS BOPI) DANS LAQUELLE : 1. R, R, R ET R, IDENTIQUES OU DIFFERENTS, DESIGNENT UN RADICAL ALKYLE, SATURE, LINEAIRE EN C-C POUVANT PORTER EN BOUT DE CHAINE OU DANS LA CHAINE, UN OU PLUSIEURS GROUPEMENT(S) HYDROXYLE(S); 2. R DESIGNE LE GROUPEMENT : (CF DESSIN DANS BOPI) DANS LEQUEL N DESIGNE UN NOMBRE ENTIER COMPRIS ENTRE 0 ET 18; R, R ET R AYANT LES MEMES SIGNIFICATIONS QUE SOUS 1.; R REPRESENTE UN HYDROGENE, UN HYDROXYLE, UN HALOGENE, UN RESTE ALKYLE OU HYDROXYALKYLE LINEAIRE EN C A C OU UN RESTE ACYLE LINEAIRE EN C A C;DANS LAQUELLE R A LES SIGNIFICATIONS INDIQUEES DANS 1. ET 2.; OU 4. R ET R DESIGNENT UN HETEROCYCLE NON AROMATIQUE, SATURE OU INSATURE, EVENTUELLEMENT INTERROMPU PAR UN ATOME D'OXYGENE ETOU D'AZOTE ETOU DE SOUFRE; R REPRESENTE UN GROUPEMENT DEFINI DANS LES PARAGRAPHES 1. ET 2. ET R REPRESENTE UN GROUPEMENT DEFINI DANS LE PARAGRAPHE 1.; 5. R, R ET R PEUVENT FORMER UN BICYCLE NON AROMATIQUE, SATURE OU INSATURE, EVENTUELLEMENT INTERROMPU PAR UN ATOME D'AZOTE; R REPRESENTE UN GROUPEMENT DEFINI DANS 1. ET 2.; R DESIGNE UN GROUPEMENT REPONDANT A LA FORMULE : -C-(CH)-CH DANS LAQUELLE N EST UN QUATERNARY AMMONIUM LIPOPHILIC SALICYLATE, CHARACTERIZED BY THE FACT THAT IT MEETS THE FORMULA: (CF DRAWING IN BOPI) IN WHICH: 1. R, R, R AND R, IDENTICAL OR DIFFERENT, DESIGNATE A RADICAL ALKYL, SATURATED, LINEAR IN CC MAY CARRY AT THE END OF THE CHAIN OR IN THE CHAIN, ONE OR MORE HYDROXYL GROUP (S); 2. R DESIGNATES THE GROUP: (CF DRAWING IN BOPI) IN WHICH N DESIGNATES A WHOLE NUMBER BETWEEN 0 AND 18; R, R AND R HAVING THE SAME MEANINGS AS UNDER 1 .; R REPRESENTS A HYDROGEN, A HYDROXYL, A HALOGEN, A LINEAR ALKYL OR HYDROXYALKYL REMAINDER IN C A C OR A LINEAR ACYL REMAINDER IN C A C; IN WHICH R HAS THE MEANINGS INDICATED IN 1. AND 2 .; OR 4. R AND R DESIGNATE A NON-AROMATIC, SATURATED OR UNSATURATED HETEROCYCLE, POSSIBLY INTERRUPTED BY AN ...

EMM-31 materials and methods of making and using same

THIOMOLYBDATE ANALOGUES AND USES THEREOF

The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation.

Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use

The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6 and their medical use, including their use in treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.

IMAGE FORMING MATERIAL AND AMMONIUM COMPOUND

PROBLEM TO BE SOLVED: To provide a positive image forming material responding to a heat mode useful for a lithographic printing master plate which is excellent in the solubility discrimination, improved in the development latitude and scratch resistance and capable of forming an image having excellent contrast and to provide a new ammonium compound to be used for the above material. SOLUTION: The image forming material has an image forming layer containing (A) a water-insoluble and alkali-soluble resin, (B) a photothermal converting agent and (C) a compound expressed by general formula (1). In the formula, each of R1 to R3 independently represents an organic group, R1 represents a residue forming a cyclic structure containing an N1 atom, R2 and R3 may be coupled to form a cyclic structure or at least either R2 or R3 may be coupled with R1 to form a cyclic structure X- represents a conjugate group of an organic acid and an inorganic acid and the cyclic structure containing the N1 atom is ...

Patent RU2018104097A3

ВУ“? 2018104097” АЗ Дата публикации: 16.12.2019 Форма № 18 ИЗИМ-2011 Федеральная служба по интеллектуальной собственности Федеральное государственное бюджетное учреждение 5 «Федеральный институт промышленной собственности» (ФИПС) ОТЧЕТ О ПОИСКЕ 1. . ИДЕНТИФИКАЦИЯ ЗАЯВКИ Регистрационный номер Дата подачи 2018104097/04(006049) 28.07.2016 РСТ/СВ2016/052312 28.07.2016 Приоритет установлен по дате: [ ] подачи заявки [ ] поступления дополнительных материалов от к ранее поданной заявке № [ ] приоритета по первоначальной заявке № из которой данная заявка выделена [ ] подачи первоначальной заявки № из которой данная заявка выделена [ ] подачи ранее поданной заявки № [Х] подачи первой(ых) заявки(ок) в государстве-участнике Парижской конвенции (31) Номер первой(ых) заявки(ок) (32) Дата подачи первой(ых) заявки(ок) (33) Код страны 1. 1513304.4 28.07.2015 СВ Название изобретения (полезной модели): [Х] - как заявлено; [ ] - уточненное (см. Примечания) ЦИКЛИЧЕСКИЕ ЧЕТВЕРТИЧНЫЕ АММОНИЕВЫЕ СОЛИ В КАЧЕСТВЕ ПРИСАДОК К ТОПЛИВУ ИЛИ СМАЗОЧНЫМ МАТЕРИАЛАМ Заявитель: ИННОСПЕК ЛИМИТЕД, СВ 2. ЕДИНСТВО ИЗОБРЕТЕНИЯ [Х] соблюдено [ ] не соблюдено. Пояснения: см. Примечания 3. ФОРМУЛА ИЗОБРЕТЕНИЯ: [Х] приняты во внимание все пункты (см. Примечания) [ ] приняты во внимание следующие пункты: [ ] принята во внимание измененная формула изобретения (см. Примечания) 4. КЛАССИФИКАЦИЯ ОБЪЕКТА ИЗОБРЕТЕНИЯ (ПОЛЕЗНОЙ МОДЕЛИ) (Указываются индексы МПК и индикатор текущей версии) (070 207/04 (2006.01) (070 231/10 (2006.01) С1ОГ. 10/18 (2006.01) (070 295/04 (2006.01) С 1ОГ. 1/232 (2006.01) С1ОМ 133/38 (2006.01) 5. ОБЛАСТЬ ПОИСКА 5.1 Проверенный минимум документации РСТ (указывается индексами МПК) С07О 207/04, СО7О 295/04,СО7Р 231/10, СЛОГ, 1/232, СТО 190/18, С1ОМ 133/38 5.2 Другая проверенная документация в той мере, в какой она включена в поисковые подборки: 5.3 Электронные базы данных, использованные при поиске (название базы, и если, возможно, поисковые термины): СТРО, СМГРА, РЕРАТЗ пе, ОУ/Р1, ЕАРАТГУ, ...

PHOTOAKTIVIERBARE STICKSTOFFHALTIGE BASEN

Salt forms of [R-(R*,R*)]-2-(4-flurorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Process for the preparation of perfluoroalkylcyano- or perfluoroalkylcyanofluoroborates

The invention relates to a process for the preparation of salts having perfluoroalkyltricyano- or perfluoroalkylcyanofluoroborate anions, ((per)fluoro)phenyltricyano- or ((per)fluoro)phenylcyanofluoroborate anions, phenyltricyanoborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms or phenylcyanofluoroborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms, by reaction of alkali metal trifluoroperfluoroalkylborate with trialkylsilyl cyanide and a subsequent salt-exchange reaction or by direct reaction of an organic trifluoroperfluoroalkyl borate with trialkylsilyl cyanide.

Synthesis of mse-framework type molecular sieves

A method of synthesizing a crystalline molecular sieve having an MSE framework type comprises crystallizing a reaction mixture comprising a source of water, a source of an oxide of a tetravalent element, Y, selected from at least one of silicon, tin, titanium, vanadium, and germanium, optionally a source of a trivalent element, X, a source of an alkali or alkaline earth metal, M, and a source of organic dications, Q, such as 3-hydroxy-1-(4-(1-methylpiperidin-1-ium-1 yl)butyl)quinuclidin-1-ium, 3-hydroxy-1-(5-(1-methylpiperidin-1-ium-1-yl)pentyl)quinuclidin-1-ium, 1,1′-(butane-1,4-diyl)bis(1-methylpiperidin-1-ium), 1,1′-(pentane-1,5-diyl)bis(1-methylpiperidin-1-ium), 1,1′-(hexane-1,6-diyl)bis(1-methylpiperidin-1-ium), and 1,1′-((3as,6as)-octahydropentalene-2,5-diyl)bis(1-methylpiperidin-1-ium).

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Diamine and meglumine salt forms of fatty acids

Provided herein are diamine salts of eicosapentaenoic acid and docosahexaenoic acid, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and the uses of such compounds as agents for treating dyslipidemia, cardiovascular diseases such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke and obesity.

METHOD FOR PRODUCING TRIARYLORGANOBORATES

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms. 1. Process for preparing triaryl organoborates of the formula 1/n KRB—R(IV) , where one equivalent of organoboronic ester of the formula B—R(OR)(OR) (I) is initially charged together with 1/n equivalents of salt K nX (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1 , 3 equivalents of a haloaromatic R—Y (III) are added , an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n K RB—R(IV) is separated off with the organic phase and{'sup': '1', 'sub': 1', '22', '3', '22', '3', '22', '5', '7', '7', '13, 'Ris an optionally hydroxyl- and/or alkoxy- and/or acyloxy- and/or halogen-substituted C- to C-alkyl, C- to C-alkenyl, C- to C-alkynyl, C- to C-cycloalkyl or C- to C-aralkyl radical,'}{'sup': 2', '3', '2', '3, 'sub': 1', '22', '3', '7, 'Rand Rare independently an optionally branched C- to C-alkyl radical or an optionally alkyl-substituted C- to C-cycloalkyl radical or Rand Rtogether form a 2-8-membered carbon bridge which is optionally substituted by alkyl and/or interrupted by oxygen atoms,'}{'sup': '4', 'sub': 6', '10', '1', '4', '1', '4, 'Ris a C- to C-aryl radical optionally substituted by at least one radical selected from halogen, C- to C-alkyl, trifluoromethyl, C- to C-alkoxy, trifluoromethoxy, phenyl and phenoxy,'}K is an organocation of valency n and having any substitution, based on nitrogen, phosphorus, oxygen, sulfur and/or iodine, and{'sup': 2', '3, 'L is an auxiliary that forms a complex of sparing solubility in S1 and/or S2 with M salts MY(OR), MY(OR) and MXY, where L is a Lewis-basic compound, especially selected from the group consisting of open chain ...

ALL-SOLID SECONDARY BATTERY AND METHOD OF PREPARING THE SAME

An all-solid secondary battery includes a cathode layer including a cathode active material layer; an anode layer; and a solid electrolyte layer disposed between the cathode layer and the anode layer, wherein the anode layer includes an anode current collector and a first anode active material layer is disposed on the anode current collector, wherein the first anode active material layer includes an organic electrolyte and an anode active material that is capable of forming an alloy with lithium or a compound with lithium, and wherein the organic electrolyte includes an organic salt including an organic cation and an anion. 1. An all-solid secondary battery comprising:a cathode layer comprising a cathode active material layer;an anode layer; anda solid electrolyte layer disposed between the cathode layer and the anode layer,wherein the anode layer comprises an anode current collector and a first anode active material layer disposed on the anode current collector,wherein the first anode active material layer comprises an organic electrolyte and an anode active material that is capable of forming an alloy with lithium or a compound with lithium, andwherein the organic electrolyte comprises an organic salt comprising an organic cation and an anion.2. The all-solid secondary battery of claim 1 , wherein the organic cation comprisesat least one of an acyclic cation comprising a Group 15 element or a heterocyclic cation comprising 1 to 3 heteroatoms.6. The all-solid secondary battery of claim 1 , wherein the organic salt comprises:at least one of an ammonium cation, a pyrrolidinium cation, a pyridinium cation, a pyrimidinium cation, an imidazolium cation, a piperidinium cation, a pyrazolium cation, an oxazolium cation, a pyridazinium cation, a phosphonium cation, a sulfonium cation, or a triazolium cation; andat least one anion.8. The all-solid secondary battery of claim 1 , wherein the anion comprises at least one of BF claim 1 , PF claim 1 , AsF claim 1 , SbF claim 1 , ...

PRODRUGS OF 4-((1R, 3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-Y)-1-,2,2-TRIMETHYLPIPERAZINE AND 4-((1R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1YL)-2,2-DIMETHYL-1 (METHYL-D3)PIPERAZINE

The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form of 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d)piperazine in the form of 2a and 2b, wherein X—is a counter ion, or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising prodrugs, or pharmaceutically acceptable salts thereof, of the invention. 2. The prodrug according to claim 1 , wherein R is linear or branched C-Calkyl claim 1 , or a pharmaceutically acceptable salt thereof.3. The prodrug according to claim 1 , wherein R is selected from the group consisting of methyl claim 1 , tertbutyl claim 1 , n-undecane and cyclohexylmethyl claim 1 , or a pharmaceutically acceptable salt thereof.4. The prodrug claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , according to claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of salts formed from hydrochloride acid claim 1 , hydrobromide acid claim 1 , phosphoric acid claim 1 , nitrous acid claim 1 , sulphuric acid claim 1 , benzoic acid claim 1 , citric acid claim 1 , gluconic acid claim 1 , lactic acid claim 1 , maleic acid claim 1 , succinic acid claim 1 , tartaric acid claim 1 , acetic acid claim 1 , propionic acid claim 1 , oxalic acid claim 1 , maleic acid claim 1 , fumaric acid claim 1 , glutamic acid claim 1 , pyroglutamic acid claim 1 , salicylic acid claim 1 , saccharin and sulfonic acids.5. The prodrug according to selected from the group consisting of (R)-1-(acetoxymethyl)-4-((1R claim 1 ,3S)-6-chloro-3-phenyl-2 claim 1 ,3-dihydro-1H-inden-1-yl)-1 claim 1 ,2 claim 1 ,2-trimethylpiperazin-1-ium claim 1 , (S)-1-(acetoxymethyl)-4-((1R claim 1 ,3S)-6-chloro-3-phenyl-2 claim 1 ,3-dihydro-1H-inden-1-yl)-1 claim 1 ,2 claim 1 ,2-trimethylpiperazin-1-ium claim 1 , (R)-1-(acetoxymethyl)-4-((1R claim 1 ,3S)-6-chloro-3 ...

CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation. 2. The compound of claim 1 , wherein Xis —NHC(O)—.3. The compound of or claim 1 , wherein each of Rand Ris independently selected from H claim 1 , halogen claim 1 , Calkyl claim 1 , Calkenyl claim 1 , Calkynyl claim 1 , and NRR; and each of Rand Ris independently selected from H claim 1 , Calkyl claim 1 , Calkenyl claim 1 , Calkynyl claim 1 , and Cheteroalkyl; or wherein at least one Ris present.4. The compound of any one of - claim 1 , wherein Ris Calkyl optionally substituted with halogen claim 1 , Ccyclic alkyl claim 1 , aryl claim 1 , or heteroaryl.5. The compound of any one of - claim 1 , wherein Ris H or Calkyl optionally substituted with halogen claim 1 , Ccyclic alkyl claim 1 , aryl claim 1 , or heteroaryl.6. The compound of any one of - claim 1 , wherein Ris Calkyl optionally substituted with halogen claim 1 , Ccyclic alkyl claim 1 , aryl claim 1 , or heteroaryl.7. The compound of any one of - claim 1 , wherein said compound is a compound in Table 1.11. The compound of claim 10 , wherein each of Rand Ris Calkyl optionally substituted with halogen claim 10 , cyclic alkyl claim 10 , aryl claim 10 , or heteroaryl.12. The compound of or claim 10 , wherein each of R claim 10 , R claim 10 , and Ris independently selected from H claim 10 , halogen claim 10 , Calkyl claim 10 , and CF; or wherein at least one Ris present; or wherein at least one Ris present.13. The compound of any one of - claim 10 , wherein said compound is a compound in Table 2.16. The compound of claim 15 , wherein Xis —NHC(O)—17. The compound of or claim 15 , wherein n is 0 or 1.18. The compound of any one of - claim 15 , wherein each of R claim 15 , R claim 15 , and Ris independently selected from H claim 15 , Calkyl claim 15 , and NRR; and each of Rand Ris independently selected from H claim 15 , Calkyl claim 15 , Calkenyl claim 15 , Calkynyl claim 15 , and ...

WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE

Provided are: a water-soluble composition which has excellent storage stability and is adaptable to a wide range of light sources and capable of forming a highly fine pattern; a method of producing a cured product of the same; a cured product of the same; and an acylphosphinate. The water-soluble composition contains: an acylphosphinate (A) represented by Formula (I) below, wherein Xrepresents an aryl group having 6 to 15 carbon atoms; Xrepresents a linear alkyl group having 1 to 8 carbon atoms or the like; A represents an alkali metal ion or the like; and m represents a number of 1 to 3; and a compound (B) having a group represented by Formula (II) below, wherein Rrepresents a hydrogen atom or the like; Zrepresents an oxygen atom or the like; Rrepresents a hydrogen atom or the like; Zrepresents an alkylene group having 1 to 6 carbon atoms; n represents a number of 0 to 30; * means a bond; and, when the compound (B) has plural groups represented by Formula (II), plural Rs, Zs, Zs and n's are each optionally the same or different. 2. The water-soluble composition according to claim 1 , wherein Xin the Formula (I) is a 2 claim 1 ,4 claim 1 ,6-trimethylphenyl group.3. The water-soluble composition according to claim 1 , wherein claim 1 , in the Formula (I) claim 1 , Xis a phenyl group and A is NHYYY.4. The water-soluble composition according to claim 1 , wherein{'sup': m+', '+', '1', '2', '3, 'A in the Formula (I) is NHYYY, and'}{'sup': 1', '2', '3, 'at least one hydrogen atom of Y, Yand Yis substituted with a hydroxy group.'}5. The water-soluble composition according to claim 1 , wherein Zin the Formula (II) is —NR—.6. The water-soluble composition according to claim 1 , further comprising a coloring agent (C).7. A method of producing a cured product claim 1 , comprising curing the water-soluble composition according to by irradiation with light or heating.8. A cured product obtained from the water-soluble composition according to .10. The acylphosphinate according to ...

EMM-23 Molecular Sieve Material, Its Synthesis and Use

A new molecular sieve material is designated as EMM-23 and has, in its as-calcined form, an X-ray diffraction pattern including the following peaks in Table 1: 114-. (canceled)16. The organic nitrogen compound of claim 15 , wherein said organic nitrogen compound is 1 claim 15 ,5-bis(N-propylpyrrolidinium)pentane dication.20. The organic nitrogen compound of claim 19 , wherein said organic nitrogen compound is 1 claim 19 ,6-bis(N-propylpyrrolidinium)pentane dication. This application claims priority to U.S. Patent Application No. 61/514,939 filed Aug. 4, 2011 and EP Application No. 11181734.2, filed Sep. 19, 2011, the disclosures of which are incorporated herein by reference in their entireties.This invention relates to a novel molecular sieve material, designated as EMM-23, its synthesis, its use as an adsorbent, and a catalyst for hydrocarbon conversion reactions.Molecular sieve materials, both natural and synthetic, have been demonstrated in the past to be useful as adsorbents and to have catalytic properties for various types of hydrocarbon conversion reactions. Certain molecular sieves, zeolites, AIPOs, mesoporous materials, are ordered, porous crystalline materials having a definite crystalline structure as determined by X-ray diffraction (XRD). Within the crystalline molecular sieve material there are a large number of cavities which may be interconnected by a number of channels or pores. These cavities and pores are uniform in size within a specific molecular sieve material. Because the dimensions of these pores are such as to accept for adsorption molecules of certain dimensions while rejecting those of larger dimensions, these materials have come to be known as “molecular sieves” and are utilized in a variety of industrial processes.Such molecular sieves, both natural and synthetic, include a wide variety of positive ion-containing crystalline silicates. These silicates can be described as rigid three-dimensional framework of SiOand Periodic Table Group 13 ...

Organo-1-oxa-4-azonium cyclohexane compounds

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained.

Preparation Of Difluoro Chelato Borate Salts

A process for preparing a difluoro chelato borate salt comprising an anion A of formula (I) 2. The process according to claim 1 , wherein the total content of additional sources for F-atoms is less than 50 mol.-% based on the total amount of BF-source (a).3. The process according to claim 1 , wherein the volatile reaction products are removed during and/or after step (i).4. The process according to claim 1 , wherein an organic solvent or solvent mixture (e) is present in the reaction mixture of step (i).5. The process according to claim 1 , wherein the BFsource (a) is selected from BF claim 1 , BFhydrate claim 1 , BFetherates claim 1 , BF-alcohol adducts claim 1 , BF-acetonitril adduct claim 1 , BF-acetic acid adduct claim 1 , and BF-amine adducts.6. The process according to claim 1 , wherein the dihydric compound (b) is selected from 1 claim 1 ,2-diols claim 1 , 1 claim 1 ,2-dicarboxylic acids claim 1 , and 1 claim 1 ,2-hydroxycarboxylic acids.7. The process according to claim 1 , wherein the dihydric compound (b) is selected from oxalic acid claim 1 , salicylic acid claim 1 , and phthalic acid.8. The process according to claim 1 , wherein the second boron source (c) is selected from boric acid claim 1 , B(OC-Calkyl) claim 1 , B(OC-C(hetero)aryl) claim 1 , and ammonium and alkali metal salts of borate complexes of the dihydric compound used as component (b).9. The process according to claim 1 , wherein the dihydric compound (b) is oxalic acid and the second boron source (c) is selected from boric acid claim 1 , lithium bis(oxalato) borate claim 1 , triethylammonium bis(oxalato)borate claim 1 , and mixtures thereof.10. The process according to claim 1 , wherein the proton acceptor (d) is selected from ammonia claim 1 , organic amines claim 1 , organic ammonium hydroxides claim 1 , NHOH claim 1 , and nitrogen containing aromatic heterocycles.11. The process according to claim 1 , wherein the proton acceptor (d) is selected from organic amines NRRR claim 1 , NHOH ...

Cycloalkyl Amine Compounds

Cycloalkyl amine compounds of Formula (I), 2. The compound of claim 1 , wherein Rand Rare both H claim 1 , and R claim 1 , R claim 1 , Rand Rare all H.3. (canceled)5. The compound of claim 4 , wherein Ris H.7. (canceled)9. The compound of claim 1 , wherein ring A is unsubstituted.10. The compound of claim 1 , wherein ring A is substituted with one or more C-Calkyl.11. The compound of claim 10 , wherein ring A is substituted with one C-Calkyl.12. The compound of claim 1 , wherein ring A is optionally substituted C-Ccycloalkyl.13. The compound of claim 12 , wherein the compound is of Formula (Ia) or (Ib) and ring A is unsubstituted cyclobutyl.14. The compound of claim 12 , wherein the compound is of Formula (Ic) and ring A is unsubstituted cyclopentyl.15. The compound of claim 12 , wherein the compound is of Formula (Ic) and ring A is optionally substituted cyclobutyl.16. The compound of claim 2 , wherein each of Rand R claim 2 , independently claim 2 , is H claim 2 , halo claim 2 , or cyano.17. The compound of claim 16 , wherein at least one of Rand Ris halo.18. The compound of claim 17 , wherein each of Rand Ris chloro.19. The compound of claim 16 , wherein Rand R claim 16 , together with the carbon atoms to which they are attached claim 16 , form phenyl claim 16 , pyridyl claim 16 , pyrrolyl claim 16 , furanyl claim 16 , thienyl claim 16 , thiazolyl claim 16 , oxazolyl claim 16 , imidazolyl claim 16 , pyrazolyl claim 16 , isoxazolyl claim 16 , triazolyl claim 16 , oxadiazolyl claim 16 , pyridazinyl claim 16 , pyrazinyl claim 16 , or pyrimidyl.20. The compound of claim 2 , wherein one of Rand Ris H and the other is C-Calkyl optionally substituted with halo or is C-Ccycloalkyl optionally substituted with C-Calkyl.21. The compound of claim 20 , wherein the other of Rand Ris isopropyl or t-butyl claim 20 , optionally substituted with one or more halo groups.22. The compound of claim 1 , wherein one of Rand Ris C-Calkyl optionally substituted with halo and the other is ...

Synthesis of ZSM-5

A molecular sieve having the framework structure of ZSM-5 is produced using one or more of 1,4-bis(N-pentylpyrrolidinium)butane dications, 1,5-bis(N-pentylpyrrolidinium)pentane dications, and 1,6-bis(N-pentylpyrrolidinium)hexane dications as a structure directing agent. 19.-. (canceled)12. The molecular sieve of claim 11 , wherein X includes aluminum claim 11 , and Y includes silicon and/or germanium.14. (canceled) The present application claims priority to and the benefit of U.S. Provisional Application No. 61/740,917 filed on 21 Dec. 2012, which is hereby incorporated by reference in its entirety.This invention relates to the synthesis of ZSM-5, and to the use of the resultant ZSM-5 as an adsorbent and a catalyst for organic conversion reactions.Crystalline ZS M-5, and its conventional preparation using tetrapropylammonium cations as a structure directing agent, are taught by U.S. Pat. No. 3,702,886 and U.S. Pat. No. Re. 29,948, the entire disclosures of which are incorporated herein by reference. Conventional ZSM-5 has a distinctive X-ray diffraction pattern which distinguishes it from organic conversion reactions.In addition to tetrapropylammonium cations, a large number of other organic nitrogen compounds, including certain diquaternary ammonium compounds, have been shown to direct the synthesis of ZSM-5. For example, U.S. Pat. No. 4,585,638 discloses that the synthesis of ZSM-5 can be directed by the diquaternary cation (alkyl)N(CH)N(alkyl), where the alkyl group is propyl or butyl.According to the present invention, it has now been found that ZSM-5 can be synthesized using certain novel bis(N-pentylpyrrolidinium)-diquat-n cations, where n=4, 5 or 6, as a structure directing agent. The ZSM-5 can be made across a wide range of Si/Al ratios (infinity to 12) and, in some cases, it has been found that novel ultra-small forms of ZSM-5 can be produced.In one aspect, the invention resides in a process for producing a molecular sieve having the framework structure of ...

Salts of fenofibric acid and pharmaceutical formulations thereof

In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.

REACTIVE IONIC LIQUIDS

The invention relates to reactive ionic liquids containing organic cations with groups or substituents which are susceptible to electrochemical reduction and anions obtained from fluoroalkyl phosphates, fluoroalkyl phosphinates, fluoroalkyl phosphonates, acetates, triflates, imides, methides, borates, phosphates and/or aluminates, for use in electrochemical cells, such as lithium ion batteries and double-layer capacitors. 3. Electrolyte comprising at least one conductive salt claim 1 , an aprotic solvent or solvent mixture claim 1 , at least one ionic liquid according to and optionally further additives.4. Electrolyte according to claim 3 , characterised in that the conductive salt is a lithium conductive salt claim 3 , such as LiPF claim 3 , LiN(SOCF) claim 3 , LiN(SOCF) claim 3 , LiFP(CF) claim 3 , LiFP(CF) claim 3 , LiB(CO)or LiFB(CO4).5. Electrolyte according to claim 3 , characterised in that the conductive salt is selected from the following compounds: N(CH)BF claim 3 , N(CH)PF claim 3 , N(CH)(CH)BF claim 3 , N(CH)(CH)PF claim 3 , N(CH)N(SOCF) claim 3 , N(CH)(CH)N(SOCF) claim 3 , N(CH)FP(CF) claim 3 , N(CH)(CH)FP(CF).6. Electrolyte according to claim 3 , characterised in that the aprotic solvent consists of organic open-chain or cyclic carbonates claim 3 , carboxylic acid esters claim 3 , nitrites claim 3 , ethers claim 3 , lactones or a mixture thereof.7. Process for the preparation of ionic liquids of the formula I according to claim 1 , comprising the following steps:{'sup': '+', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'Preparation of heterocyclic cations K having alkyl-, carboxylate-, carbonate- or cyano-containing side chains according to as onium chlorides or bromides from the corresponding amines, phosphines, halocarboxylates, halocarbonates, haloalkyl nitriles or alkyl halides by conventional wet-chemical methods'}Reaction of these cationic onium chlorides or bromides the corresponding anionic potassium and/or, sodium fluoroalkylphosphates and ...

SYNTHESIS OF ZEOLITES USING AN ORGANOAMMONIUM COMPOUND

A method for synthesizing a zeolite includes the steps of: (a) preparing an aqueous mixture comprising water, a substituted hydrocarbon and an amine; (b) reacting the aqueous mixture; (c) obtaining a solution comprising an organoammonium product; (d) forming a reaction mixture including reactive sources of M, Al, Si, optionally seeds of a layered material L, and the solution, wherein M is a metal; and (e) heating the reaction mixture to form the zeolite. The substituted hydrocarbon can be an α,ω-dihalogen substituted alkane, and the amine is preferably essentially incapable of undergoing pyramidal inversion. 1. A method for synthesizing a zeolite , the method comprising:(a) preparing an aqueous mixture comprising water, a substituted hydrocarbon and an amine other than trimethylamine wherein the amine is a tertiary amine or secondary amine having 9 or less carbon atoms and being essentially incapable of undergoing pyramidal inversion, or combinations thereof;(b) reacting the aqueous mixture;(c) obtaining a solution comprising an organoammonium product;(d) forming a reaction mixture including reactive sources of M, Al, Si, optionally seeds of a layered material L, and the solution, wherein M is a metal; and(e) heating the reaction mixture to form the zeolite.2. The method of claim 1 , wherein the step of reacting the aqueous mixture occurs at a temperature from about 20° C. to about 100° C.3. The method of claim 1 , wherein the organoammonium product is a structure directing agent.4. The method of wherein the substituted hydrocarbon is selected from the group consisting of halogen substituted alkanes having from 2 to 8 carbon atoms claim 1 , α claim 1 ,ω-dihalogen substituted alkanes having from 3 to 6 carbon atoms claim 1 , di-halogen substituted alkanes having from 3 to 8 carbon atoms claim 1 , tri-halogen substituted alkanes having from 3 to 8 carbons and combinations thereof.5. The method of wherein the substituted hydrocarbon is a halogen substituted alkane ...

PROCESS FOR THE PREPARATION OF PERFLUOROALKYLCYANO- OR PERFLUOROALKYLCYANOFLUOROBORATES

The invention relates to a process for the preparation of salts having perfluoroalkyltricyano- or perfluoroalkylcyanofluoroborate anions, ((per)fluoro)phenyltricyano- or ((per)fluoro)phenylcyanofluoroborate anions, phenyltricyanoborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms or phenylcyanofluoroborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms, by reaction of alkali metal trifluoroperfluoroalkylborate with trialkylsilyl cyanide and a subsequent salt-exchange reaction or by direct reaction of an organic trifluoroperfluoroalkyl borate with trialkylsilyl cyanide. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. A salt of formula III{'br': None, 'sup': a+', '−, 'sub': f', 'x', 'y', 'a, 'M[B(R)(CN)(F)]\u2003\u2003III,'}where{'sup': 'a+', 'M is a lithium, potassium, sodium, caesium or rubidium salt,'}{'sub': f', '6', '5', '6', '5, 'Rdenotes a linear or branched perfluorinated alkyl group having 1 to 4 C atoms, CF, CH, partially fluorinated phenyl, or phenyl which is mono- or disubstituted by a perfluoroalkyl group having 1 to 4 C atoms, where the perfluoroalkyl group is selected independently of one another,'}a is 1,x is 1, 2 or 3,{'sub': f', '6', '5, 'y is 0, 1 or 2, where 0 is excluded for R═CH, and'}x+y is 3.11. A salt according to claim 10 , that is potassium trifluoromethyltricyanoborate claim 10 , potassium pentafluoroethyltricyanoborate claim 10 , potassium heptafluoropropyltricyanoborate claim 10 , potassium trifluoromethyldicyanofluoroborate claim 10 , potassium pentafluoroethyldicyanofluoroborate claim 10 , potassium heptafluoropropyldicyanofluoroborate claim 10 , potassium trifluoromethylmonocyanodifluoroborate claim 10 , potassium pentafluoromethylmonocyanodifluoroborate claim 10 , potassium heptafluoropropylmonocyanodifluoroborate claim 10 , potassium nonafluorobutylmonocyanodifluoroborate claim 10 ...

CATALYST COMPRISING A MIXTURE OF AN AFX-STRUCTURE ZEOLITE AND A BEA-STRUCTURE ZEOLITE AND AT LEAST ONE TRANSITION METAL FOR SELECTIVE REDUCTION OF NOX

The invention relates to a catalyst comprising a mixture of AFX-structure and BEA-structure zeolites and at least one additional transition metal, to the process for preparing same and to the use thereof for the selective catalytic reduction of NOx in the presence of a reducing agent such as NHor H. 1. A process for preparing a catalyst comprising a mixture of AFX-structure and BEA-structure zeolites , and at least one transition metal , comprising at least the following steps:{'sub': 2', '2', '3', '2', '2', '3', 'ze', '2', '2', '3', '2', '2', '3', '2', '2', '3', 'ze, 'i) mixing, in aqueous medium, of an FAU zeolite having an SiO/AlOmolar ratio of between 30 and 100 with at least one FAU-structure zeolite having an SiO/AlOmolar ratio of between 2 and 30 (upper limit excluded), and wherein the mathematical parameter, P, corresponding to the mass percentage of the FAU zeolite with an SiO/AlOmolar ratio of between 30 and 100, in its anhydrous form (expressed in %) in the mixture of FAU zeolites, multiplied by the SiO/AlOmolar ratio of the same FAU zeolite with an SiO/AlOmolar ratio of between 30 and 100, is such that: 3250 Подробнее

POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTING CELLULOSIC MATERIALS USING SUCH CATALYSTS

Provided herein are catalysts useful in non-enzymatic saccharification processes. The catalysts can be polymeric catalysts or solid-supported catalysts with acidic and ionic moieties. Provided are also methods for hydrolyzing cellulosic materials into monosaccharides and/or oligosaccharides using the catalysts described herein. 1. A catalyst comprising a solid support , acidic moieties attached to the solid support , and ionic moieties attached to the solid support ,wherein the solid support comprises a material, wherein the material is selected from the group consisting of carbon, silica, silica gel, alumina, magnesia, titania, zirconia, clays, magnesium silicate, silicon carbide, zeolites, ceramics, and any combinations thereof,wherein each acidic moiety independently has at least one Bronsted-Lowry acid, andwherein each ionic moiety independently has at least one nitrogen-containing cationic group or at least one phosphorous-containing cationic group, or a combination thereof.2. The catalyst of claim 1 , wherein each Bronsted-Lowry acid is independently selected from the group consisting of sulfonic acid claim 1 , phosphonic acid claim 1 , acetic acid claim 1 , isophthalic acid claim 1 , boronic acid claim 1 , and perfluorinated acid.3. The catalyst of claim 1 , wherein one or more of the acidic moieties are directly attached to the solid support.4. The catalyst of claim 1 , wherein one or more of the acidic moieties are attached to the solid support by a linker.5. The catalyst of claim 1 , wherein each ionic moiety is selected from the group consisting of pyrrolium claim 1 , imidazolium claim 1 , pyrazolium claim 1 , oxazolium claim 1 , thiazolium claim 1 , pyridinium claim 1 , pyrimidinium claim 1 , pyrazinium claim 1 , pyradizimium claim 1 , thiazinium claim 1 , morpholinium claim 1 , piperidinium claim 1 , piperizinium claim 1 , pyrollizinium claim 1 , phosphonium claim 1 , trimethyl phosphonium claim 1 , triethyl phosphonium claim 1 , tripropyl phosphonium ...

IONIC LIQUIDS AND PREPARATION METHOD THEREOF

The present disclosure provides an ionic liquid and a preparation method thereof, in particular, the present disclosure provides an ionic liquid whose halogen anions content and moisture content are low, and a method for preparing the same. The total content of halogen anions in the ionic liquid is less than 10 ppm, and moisture content in the ionic liquid is less than 50 ppm. The ionic liquid prepared by the method of the present disclosure is suitable for electrochemical systems which have high requirements for moisture content, such as lithium ion secondary batteries and electrochemical supercapacitors. 1. An ionic liquid , wherein a total content of halogen anions in the ionic liquid is less than 10 ppm , and moisture content in the ionic liquid is less than 50 ppm; the halogen anions are Cl , Br and I.2. The ionic liquid of claim 1 , wherein the total content of halogen anions in the ionic liquid is less than 5 ppm.5. A preparation method of the ionic liquid as described in claim 1 , comprising the following steps: [{'br': None, 'sub': 4', '5', '6', '1', '2', '3', '4', '5', '6', '1', '2', '3, 'sup': +', '−', '+', '−, 'QQQN+[QQQNH]A→[QQQNH]A+QQQN\u2003\u2003(a); or'}, {'br': None, 'sub': 4', '5', '6', '1', '2', '3', '4', '5', '6', '1', '2', '3, 'sup': +', '−', '+', '−, 'QQQP+[QQQPH]A→[QQQPH]A+QQQP\u2003\u2003(b); or'}, {'br': None, 'sub': 4', '5', '6', '1', '2', '3', '4', '5', '6', '1', '2', '3, 'sup': +', '−', '+', '−, 'QQQN+[QQQPH]A→[QQQNH]A+QQQP\u2003\u2003(c); or'}, {'br': None, 'sub': 4', '5', '6', '1', '2', '3', '4', '5', '6', '1', '2', '3, 'sup': +', '−', '+', '−, 'QQQP+[QQQNH]A→[QQQPH]A+QQQN\u2003\u2003(d);'}], 'Step 1: preparing an ammonium salt or a phosphonium salt, reaction equations as below [{'br': None, 'sub': 4', '5', '6', '3', '4', '5', '6', '2, 'sup': +', '−', '+', '−, '[QQQNH]A+RCOR′→[QQQNR]A+R′OH+CO; or'}, {'br': None, 'sub': 4', '5', '6', '3', '4', '5', '6', '2, 'sup': +', '−', '+', '−, '[QQQPH]A+RCOR′→[QQQPR]A+R′OH+CO;'}], 'Step 2: the ...

Peripherally-acting cannabinoid receptor agonists for chronic pain

Peripherally acting cannabinoid agonist compounds, pharmaceutical compositions, and methods of using them are presented.

EMM-23 Molecular Sieve Materials, Its Synthesis and Use

A new molecular sieve material is designated as EMM-23 and has, in its as-calcined form, an X-ray diffraction pattern including the following peaks in Table 1: 3. The material of claim 2 , wherein X includes one or more of B claim 2 , Al claim 2 , Fe claim 2 , and Ga claim 2 , and Y includes one or more of Si claim 2 , Ge claim 2 , Sn claim 2 , Ti claim 2 , and Zr.4. The material of claim 2 , wherein X includes aluminum claim 2 , and Y includes silicon and/or germanium.7. The material of claim 6 , wherein X includes aluminum claim 6 , and Y includes silicon.8. The material of claim 6 , wherein X includes one or more of B claim 6 , Al claim 6 , Fe claim 6 , or Ga claim 6 , and Y includes one or more of Si claim 6 , Ge claim 6 , Sn claim 6 , Ti claim 6 , or Zr.9. The material of claim 6 , wherein F includes one or more of F claim 6 , HF claim 6 , NHF claim 6 , and NHHF.10. The material of claim 6 , wherein Q comprises 1 claim 6 ,5-bis(N-propylpyrrolidinium)pentane dications and/or 1 claim 6 ,6-bis(N-propylpyrrolidinium)hexane dications.11. A process for producing the molecular sieve material of claim 6 , the process comprising the steps of:(i) preparing a synthesis mixture capable of forming said material, said mixture comprising water, a source of hydroxyl ions, a source of an oxide of a tetravalent element Y, a source of a trivalent element X, optionally a source of fluoride ions, and a directing agent (Q) comprising 1,5-bis(N-propylpyrrolidinium)pentane dications and/or 1,6-bis(N-propylpyrrolidinium)hexane dications, and said mixture having a composition, in terms of mole ratios, within the following ranges:{'sub': 2', '2', '3, 'YO/XOat least 10;'}{'sub': 2', '2, 'HO/YOabout 0.5 to about 30;'}{'sup': '−', 'sub': '2', 'OH/YOabout 0.1 to about 1.0;'}{'sub': '2', 'F/YOabout 0.0 to about 0.25; and'}{'sub': '2', 'Q/YOabout 0.05 to about 0.5;'}(ii) heating said mixture under crystallization conditions including a temperature of from about 100° C. to about 200° C. and a ...

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Photopolymer formulation for production of holographic media comprising borates with low tg

The invention relates to a photopolymer formulation comprising a component reactive toward isocyanates, a polyisocyanate component, a writing monomer and a photoinitiator containing at least one dye and a coinitiator, characterized in that the coinitiator contains at least one substance of the formula (Ia) The invention further provides a process for preparing the specific coinitiators and the coinitiators obtainable by this process, and additionally a process for producing a holographic medium using the specific coinitiators, and a holographic medium obtainable using the inventive photopolymer formulation. The invention further relates to a laminate structure comprising an inventive holographic medium and likewise specific borates suitable as coinitiators.

Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use

The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6 and their medical use, including their use in treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.

PROCESS FOR MODIFYING ISOCYANATES WITH USE OF CYCLIC AMMONIUM SALTS AS CATALYST

The invention relates to a process for modifying isocyanates where at least one organic isocyanate with NCO functionality >1 is oligomerized in the presence of at least one catalyst, characterized in that the catalyst comprises, as isocyanatemodification catalysts, at least one cyclic ammonium salt having a cation of the formula (I) (formula I), where the N-containing substituents Rand Rare mutually independently identical or different aliphatic, cycloaliphatic, aromatic or araliphatic C, to Cmoieties which are saturated or unsaturated, linear or branched, optionally substituted and/or interrupted by heteroatoms from the group of oxygen, sulphur and nitrogen, and Y is a substituted or unsubstituted, linear or branched Cto Csegment optionally interrupted by heteroatoms from the group of oxygen, sulphur and nitrogen or else intempted by aromatic rings, and optionally containing other rings. The invention further relates to the use of such a catalyst. 2. The process as claimed in claim 1 , characterized in that Rand Rare mutually independently identical or different C-C-alkyl substituents claim 1 , preferably identical or different C-C-alkyl substituents and particularly preferably have a linear structure.3. The process as claimed in claim 1 , characterized in that Rand Rin formula I are mutually independently identical or different benzyl radicals optionally substituted on the aromatic ring.4. The process as claimed in any of the preceding claims claim 1 , characterized in that segment Y is C-C-alkylene chains optionally substituted and/or interrupted by heteroatoms from the group of oxygen claim 1 , sulfur claim 1 , nitrogen and also by aromatic rings and especially has a linear structure.5. The process as claimed in any of the preceding claims claim 1 , characterized in that the anion of the cyclic ammonium salt is selected from hydroxide claim 1 , alkanoate claim 1 , carboxylate claim 1 , heterocycles having at least one negatively charged nitrogen atom in the ring ...

NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS

Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor. 114-. (canceled)15. A method of modulating the activity of a nicotinic acetylcholine receptor in an animal or human subject by administering to said subject therapeutically effective doses of a silent agonist of the nicotinic acetylcholine receptor and a nicotinic acetylcholine receptor positive allosteric modulator (PAM).16. The method of claim 15 , wherein the silent agonist of the nicotinic acetylcholine receptor and the nicotinic acetylcholine receptor positive allosteric modulator (PAM) are administered to the subject simultaneously or as consecutive doses.18. The method of claim 15 , wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is a type II PAM.19. The method of claim 18 , wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is the type II PAM 1-(5-chloro-2 claim 18 ,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl )urea (PNU-120596).20. (canceled) This application claims priority to U.S. Provisional Application No. 62/241,885, entitled “DISSECTION OF N,N-DIETHYL-N′-PHENYLPIPERAZINES AS NICOTINIC RECEPTOR SILENT AGONISTS” filed on Oct. 15, 2015, the entirety of which is herein incorporated by reference.This invention was made with Government support under contract GM57481 awarded by the National Institutes of Health. The Government has certain rights in the invention.The present ...

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained. 1. A morpholinium compound comprising: {'chemistry': {'@id': 'CHEM-US-00001', '@num': '00001', 'img': {'@id': 'EMI-C00001', '@he': '19.47mm', '@wi': '31.24mm', '@file': 'US20180258058A1-20180913-C00001.TIF', '@alt': 'embedded image', '@img-content': 'chem', '@img-format': 'tif'}}, 'br': None, 'sub': 1', '2', '3', '4', '9', '10', '5', '6', '7', '8, 'sup': +', '−, '2-R-2-R-3-R-3-R-4-R-4-R-5-R-5-R-6-R-6-R-1-oxa-4-azoniumcyclohexane-X,\u2003\u2003Formula 1, 'a 1-oxa-4-azonium cyclohexane salt having a structure of{'sub': 1', '9', 'n', '2n+1', '10', 'n', '2n+1', 'p', '2p−1, 'wherein R-Rare independently selected from H or an alkyl group having the formula CH, Ris selected from an alkyl group having the formula CHwhere n is in the range from 1 to 4, benzyl, 1-methylnaphthalene, 2-methylnaphthalene and a non-olefinic alkyl group having the formula CHwhere p is in the range from 4 to 10, X is halide or hydroxide, and the total number of C atoms in the molecule is in the range of 4 to 16;'}or combinations thereof.2. The morpholinium compound of wherein X is hydroxide.3. The morpholinium compound of wherein R-Rare H.4. The morpholinium compound of wherein at least one of Rand Ris the alkyl group having the formula CH.5. The morpholinium compound of wherein at least one of R-Ris an alkyl group.6. The morpholinium compound of wherein at least one of Rand Ris an alkyl group having the formula CH.7. The morpholinium ...

NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS

Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor. 120-. (canceled)22. The compound of claim 21 , wherein R claim 21 , R claim 21 , and Ris each independently a hydrogen claim 21 , a methyl claim 21 , cyano claim 21 , methoxy claim 21 , a halogen claim 21 , trihaloalkyl claim 21 , a carboxamide claim 21 , pentafluorosulfanyl claim 21 , or hydroxyl.23. The compound of claim 21 , wherein R claim 21 , R claim 21 , and Ris each independently a hydrogen claim 21 , a methyl claim 21 , cyano claim 21 , methoxy claim 21 , a halogen claim 21 , a trihaloalkyl claim 21 , a carboxamide claim 21 , pentafluorosulfanyl claim 21 , or hydroxyl claim 21 , and Ris hydrogen.24. The compound of claim 21 , wherein:{'sub': 1', '2', '3, 'when Ris a methyl or a CN, Rand Rare each hydrogen;'}{'sub': 1', '2', '3, 'when Ris a methoxy, Ris hydrogen Ris hydrogen or methoxy;'}{'sub': 1', '2', '3, 'when Ris a halogen, Rand Rare each hydrogen;'}{'sub': 1', '2', '3, 'when Ris a trifluoromethyl, Rand Rare each hydrogen;'}{'sub': 1', '2', '3, 'when Ris a carboxamide, pentafluorosulfanyl, Rand Rare each hydrogen;'}{'sub': 1', '3', '2, 'when Rand Rare each hydrogen, Ris a methyl, a CN, a methoxy, a halogen, a trifluoromethyl, or a carboxamide, or OH; and'}{'sub': 1', '2', '3, 'when Rand Rare each hydrogen, Ris a methyl or Cl.'}26. The pharmaceutical composition of claim 25 , wherein R claim 25 , R claim 25 , and Ris each independently a ...

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained. 1. A morpholinium compound comprising a 1-oxa-4-azonium cyclohexane salt having a structure of:{'chemistry': {'@id': 'CHEM-US-00001', '@num': '00001', 'img': {'@id': 'EMI-C00001', '@he': '25.91mm', '@wi': '61.64mm', '@file': 'US20180265485A1-20180920-C00001.TIF', '@alt': 'embedded image', '@img-content': 'chem', '@img-format': 'tif'}}, 'br': None, 'sub': 1', '2', '3', '4', '9', '10', '5', '6', '7', '8, 'sup': +', '−, '2-R-2-R-3-R-3-R-4-R-4-R-5-R-5-R-6-R-6-R-1-oxa-4-azoniumcyclohexane-X,'}{'sub': 1', '8', 'n', '2n+1', '1', '8', '9', '10', 'm', '2m, 'wherein R-Rare independently selected from H or an alkyl group having the formula CHwhere n is in the range from 1 to 4; at least one of R-Ris an alkyl group; Rand Rform a cyclic alkyl group having the formula CHforming a heterocycle of ring size q, where m is in the range from 4 to 8, and q is in the range of 5 to m+1; X is hydroxide; and the total number of C atoms in the molecule is in a range of 8 to 17.'}2. The morpholinium compound of having the Formula 1 claim 1 , wherein at least two of R-Rare an alkyl group.3. The morpholinium compound of having the Formula 1 claim 1 , wherein at least two of R-Rare an alkyl group claim 1 , and wherein at least two of R-Rare the same alkyl group.4. The morpholinium compound of having the Formula 1 claim 1 , wherein the at least two of R-Rare Rand R claim 1 , or Rand R claim 1 , or Rand R claim 1 , or Rand R.5. A ...

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained. 2. The morpholinium compound of wherein X is hydroxide.3. The morpholinium compound of wherein R-Rare H.4. The morpholinium compound of wherein at least one of R-Ris an alkyl group.5. The morpholinium compound of wherein x is 1 claim 1 , and y is m.6. The morpholinium compound of wherein when Ris an alkyl group and X is hydroxide.7. The morpholinium compound of wherein Ris an alkyl group and n is 1 claim 1 , m is 4 claim 1 , x is 1 claim 1 , and y is 4.8. The morpholinium compound of wherein at least two of R-Rare the alkyl group claim 1 , and wherein the at least two of R-Rare Rand R claim 1 , or Rand R claim 1 , or Rand R claim 1 , or Rand R.9. The morpholinium compound of wherein at least two of R-Rare an alkyl group claim 1 , and wherein at least two of R-Rare the same alkyl group.10. A method for synthesizing a 1-oxa-4-azonium cyclohexane salt claim 1 , comprising:preparing an aqueous mixture comprising water, a substituted hydrocarbon, and a 1-oxa-4-azacyclohexane derivative;reacting the aqueous mixture;obtaining a solution comprising the 1-oxa-4-azonium cyclohexane salt; andwherein the mixture and the solution are essentially free of aluminum and silicon. This application is a Continuation-In-Part of copending U.S. application Ser. No. 15/334,154 filed Oct. 25, 2016, which application is a Division of U.S. application Ser. No. 14/561,132 filed Dec. 4, 2014, now U.S. Pat. No. 9,522,896 issued Dec. 20 ...

METHOD FOR PRODUCING TRIARYLORGANOBORATES

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms. 1. Process for preparing triaryl organoborates of the formula 1/n KRB—R(IV) , where one equivalent of organoboronic ester of the formula B—R(OR)(OR) (I) is initially charged together with 1/n equivalents of salt KnX (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1 , 3 equivalents of a haloaromatic R—Y (III) are added , an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n KRB—R(IV) is separated off with the organic phase and{'sup': '1', 'sub': 1', '22', '3', '22', '3', '22', '5', '7', '7', '13, 'Ris an optionally hydroxyl- and/or alkoxy- and/or acyloxy- and/or halogen-substituted C- to C-alkyl, C- to C-alkenyl, C- to C-alkynyl, C- to C-cycloalkyl or C- to C-aralkyl radical,'}{'sup': 2', '3', '2', '3, 'sub': 1', '22', '3', '7, 'Rand Rare independently an optionally branched C- to C-alkyl radical or an optionally alkyl-substituted C- to C-cycloalkyl radical or Rand Rtogether form a 2-8-membered carbon bridge which is optionally substituted by alkyl and/or interrupted by oxygen atoms,'}{'sup': '4', 'sub': 6', '10', '1', '4', '1', '4, 'Ris a C- to C-aryl radical optionally substituted by at least one radical selected from halogen, C- to C-alkyl, trifluoromethyl, C- to C-alkoxy, trifluoromethoxy, phenyl and phenoxy,'}K is an organocation of valency n and having any substitution, based on nitrogen, phosphorus, oxygen, sulfur and/or iodine, and{'sup': 2', '3, 'L is an auxiliary that forms a complex of sparing solubility in S1 and/or S2 with M salts MY(OR), MY(OR) and MXY, where L is a Lewis-basic compound, especially selected from the group consisting of open chain or ...

NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS

Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor. 2. The compound of claim 1 , wherein R claim 1 , R claim 1 , and Ris each independently a hydrogen claim 1 , a methyl claim 1 , cyano claim 1 , methoxy claim 1 , a halogen claim 1 , trihaloalkyl claim 1 , a carboxamide claim 1 , pentafluorosulfanyl claim 1 , or hydroxyl.3. The compound of claim 1 , wherein R claim 1 , R claim 1 , and Ris each independently a hydrogen claim 1 , a methyl claim 1 , cyano claim 1 , methoxy claim 1 , a halogen claim 1 , a trihaloalkyl claim 1 , a carboxamide claim 1 , pentafluorosulfanyl claim 1 , or hydroxyl claim 1 , and Ris hydrogen.4. The compound of claim 1 , wherein:{'sub': 1', '2', '3, 'when Ris a methyl or a CN, Rand Rare each hydrogen;'}{'sub': 1', '2', '3, 'when Ris a methoxy, Ris hydrogen Ris hydrogen or methoxy;'}{'sub': 1', '2', '3, 'when Ris a halogen, Rand Rare each hydrogen;'}{'sub': 1', '2', '3, 'when Ris a trifluoromethyl, Rand Rare each hydrogen;'}{'sub': 1', '2', '3, 'when Ris a carboxamide, pentafluorosulfanyl, Rand Rare each hydrogen;'}{'sub': 1', '3', '2, 'when Rand Rare each hydrogen, Ris a methyl, a CN, a methoxy, a halogen, a trifluoromethyl, or a carboxamide, or OH;'}{'sub': 1', '2', '3, 'when Rand Rare each hydrogen, Ris a methyl or Cl; and'}{'sub': '4', 'Ris an ethyl group.'}5. (canceled)7. The pharmaceutical composition of claim 6 , wherein R claim 6 , R claim 6 , and Ris each independently a ...

BASIC CYCLIC AMINO-AMMONIUM IONIC LIQUIDS COMPOSITIONS AND ELEMENTS INCLUDING THE SAME

An electrically debondable adhesive composition is described. The adhesive is comprised of a basic ionic liquid and an optionally crosslinked polymer, wherein the basic ionic liquid is comprised of a cyclic amino-ammonium cation and a bis(fluorosulfonyl)imide anion. 2. The basic ionic liquid composition of claim 1 , wherein R claim 1 , R claim 1 , and Rare independently H claim 1 , —CH claim 1 , —CHCH claim 1 , —CHCHCH claim 1 , —CHOCH claim 1 , —CHCHOCH claim 1 , —CHOCHCH claim 1 , —CHCHCHOCH claim 1 , —CHOCHCHCH claim 1 , —CHCHOCHCH claim 1 , —CHCHCHOCHCH claim 1 , —CHCHCHOCHCHCH claim 1 , or —CHCHOCHCHCH claim 1 , —CHOH claim 1 , —CHCHOH claim 1 , —CHCHCHOH claim 1 , or —CHCHCHCHOH.4. The basic ionic liquid composition of claim 1 , wherein Ris F.6. An adhesive composition comprising the basic ionic liquid composition of .7. The adhesive composition of further comprising a polymer claim 6 , wherein the polymer comprises acrylic acid claim 6 , Chydrocarbyl acrylate or Chydrocarbyl methacrylate monomers.89.-. (canceled)10. The adhesive composition of claim 7 , wherein the polymer is crosslinked with N claim 7 ,N claim 7 ,N′ claim 7 ,N′-tetraglycidyl-m-xylenediamine.1114.-. (canceled)15. A structure comprising: 1) a first electro-conductive surface 10 , 2) a second electro-conductive surface 10 , and 3) the adhesive composition of claim disposed between the first electro-conductive surface and the second electro-conductive surface.16. The structure of claim 15 , further comprising a power supply wherein at least one of the first electro-conductive surface and the second electro-conductive surface are in electrical communication with a DC power supply claim 15 , creating a closeable electrical circuit claim 15 , wherein the DC power supply is about 3 volts to about 100 volts.17. (canceled)18. The structure of claim 15 , wherein the first electro-conductive surface or the second electro-conductive surface comprises an electro-conductive metal claim 15 , a mixed metal ...

QUARTERNARY AMMONIUM PERFLUOROALKOXY SALTS FOR PREPARATION OF PERFLUOROPOLYETHERS

The present invention relates to anhydrous tetraalkyl pnictogen perfluoroalkoxy salts and a process to produce anhydrous tetraalkyl pnictogen perfluoroalkoxy salts. The process involves contacting a hydrofluoroether and an amine to produce a tetraalkyl pnictogen perfluoroalkoxy salt in the presence of a solvent. The present invention also relates to processes of preparing fluoroalkyl ether acid fluoride polymers using tetraalkyl pnictogen perfluoroalkoxy salt. The present invention further relates to some novel fluorinated alkyl polyether polymers. 1. A process to produce anhydrous tetraalkyl pnictogen perfluoroalkoxy salts comprising contacting a hydrofluoroether and an amine to produce the tetraalkyl pnictogen perfluoroalkoxy salt in the presence of a solvent.2. A process of claim 1 , further comprising decomposing the tetraalkyl pnictogen perfluoroalkoxy salt to produce a tetraalkyl pnictogen fluoride salt and a perfluoroalkyl acid fluoride.3. A process of claims 2 , further comprising separating the tetraalkyl pnictogen fluoride salt from the perfluoroalkyl acid fluoride and the solvent.4. A process of claim 1 , wherein the hydrofluoroether is R—O—R wherein Ris a linear claim 1 , branched or cyclic fluoroalkyl of 1 to 10 carbons optionally substituted by Cl claim 1 , Br or I claim 1 , non-fluorinated aryls claim 1 , or non-fluorinated cyclic groups of formula —CYwherein each Y is independently H claim 1 , O—R′ claim 1 , Cl claim 1 , Br or I wherein —R′ is an linear claim 1 , branched or cyclic alkyl of 1 to 10 carbons; and —R is methyl claim 1 , ethyl claim 1 , or propyl.6. A process of claim 1 , wherein the solvent is a hydrofluoroether.7. A process for the preparation of a fluoroalkyl ether acid fluoride polymer comprising contacting an initiator comprising one or more anhydrous quaternary pnictogen salts with one or more monomers comprising perfluoroalkylene epoxide claim 1 , perfluoroalkylene claim 1 , partially fluorinated alkylene epoxide claim 1 , or ...

PREPARATION OF FLUOROSULFONATE ESTERS AND ONIUM SALTS DERIVED THEREFROM

The present invention is directed to methods for preparing a fluorosulfonate ester or a salt thereof, through a reaction of a dissolved sulfonyl fluoride (RSOF) with alkoxide anion (RO) optionally in the presence of an aprotic base (B), where Ris fluorine or a C-Cperfluoroalkyl group, and R is a primary alkyl or alkoxyalkyl. Alkoxide anion (RO) can be generated from a precursor such as an alcohol or silyl ester. 1. A method for preparing a fluorosulfonate ester or a salt thereof , comprising:{'sub': F', '2', 'F', '1', '8, 'sup': '−', 'reacting a dissolved sulfonyl fluoride (RSOF) with an alkoxide anion (RO) precursor in the presence of an aprotic base (B), wherein Ris fluorine or a C-Cperfluoroalkyl group, and R is a primary alkyl or alkoxyalkyl group.'}2. The method of claim 1 , wherein Ris fluorine and the sulfonyl fluoride is SOF.3. The method of claim 1 , wherein the alkoxide anion (RO) precursor is a primary alcohol (ROH).4. The method of claim 1 , wherein the alkoxide anion (RO) precursor is a silyl ether having a formula ROSiR″ claim 1 , (RO)SiR″ claim 1 , (RO)SiR″ or (RO)Si claim 1 , and R″ is an alkyl group.5. The method of claim 1 , wherein the aprotic base (B) is a tertiary amine (R′N) claim 1 , wherein each R′ is independently a C-Calkyl or alkoxyalkyl claim 1 , a cycloalkyl claim 1 , morpholinyl claim 1 , or bicycloalkyl group.6. The method of claim 1 , wherein the aprotic base is a heteroaromatic tertiary amine.7. The method of claim 1 , wherein the reaction is conducted at or below atmospheric pressure.8. The method of claim 1 , further comprising: isolating a resulting fluorosulfonate ester RSOR.9. The method of claim 8 , wherein the alkoxide anion (RO) precursor is a hindered primary alkoxide.10. The method of claim 8 , wherein the aprotic base is a hindered base.11. The method of claim 1 , further comprising: isolating a resulting onium salt [RB][RSO].12. The method of claim 11 , wherein the resulting onium salt [RB][RSO] is obtained by reacting a ...

SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR

A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent RCHMgX to form the corresponding diol product, dehydrating the diol product to the corresponding dialkene; and hydrogenating the diol product to form the corresponding aniline. The 2,6 disubstituted anilines can be used to produce N-Heterocyclic Carbenes (NHCs). The NHCs can find application in various fields such as organic synthesis, catalysis and macromolecular chemistry. Palladium catalysts containing the NHCs are also described. 113-. (canceled)15. The method of wherein the groups Z claim 14 , Zand Zare H.16. The method of wherein the groups Zand Zare H and the group Zis selected from methyl claim 14 , methoxy and —NMe.1723-. (canceled)2530-. (canceled)32. The method of claim 24 , wherein the groups Z claim 24 , Zand Zare H.33. The method of claim 31 , wherein the groups Z claim 31 , Zand Zare H.34. The method of claim 14 , wherein X is an anion of halogen.35. The method of claim 14 , wherein X is an anion of chloride claim 14 , bromide claim 14 , or iodine.36. The method of claim 24 , wherein X is an anion of halogen.37. The method of claim 24 , wherein X is an anion of chloride claim 24 , bromide claim 24 , or iodine.38. The method of claim 24 , wherein Ris selected from H claim 24 , methyl claim 24 , ethyl and n-propyl.39. The method of claim 31 , wherein Ris selected from H claim 31 , methyl claim 31 , ethyl and n-propyl.40. The method of claim 32 , wherein Ris selected from H claim 32 , methyl claim 32 , ethyl and n-propyl. This application is a continuation application of U.S. patent application Ser. No. 15/852,367, filed Dec. 22, 2017, which is a continuation application of U.S. patent application Ser. No. 14/759,595, filed Jul. 7, 2015, now U.S. Pat. No. 9,890,125, which was filed under the provisions of 35 U.S.C. § 371 and claims the benefit of International Patent Application No. PCT/GB2014/050021, filed on Jan. 6, ...

水溶性組成物、その硬化物の製造方法、およびその硬化物、並びにアシルホスフィン酸塩

イオン液体および柔粘性結晶

本発明は、アニオンとカチオンから構成されるイオン液体又は柔粘性結晶であって、アニオンが［Ｃ（ＳＯ２Ｆ）３］−を含み、カチオンが1-エチル-3-メチルイミダゾリウム（［ＥＭＩ］＋）、N,N-ジエチル-N-メチル-(2-メトキシエチル)アンモニウム（［ＤＥＭＥ］＋）、N-メチル-N-プロピルピロリジニウム（［Ｐｙ１３］＋）、N-メチル-N-プロピルピペリジニウム（［ＰＰ１３］＋）、テトラメチルアンモニウム（［Ｎ１１１１］＋）、テトラエチルアンモニウム（［Ｎ２２２２］＋）、トリメチルヘキシルアンモニウム（［Ｎ６１１１］＋）、トリエチルヘキシルアンモニウム（［Ｎ６２２２］＋）、N-メチル-N-エチルピロリジニウム（［Ｐｙ１２］＋）、1-ブチル-3-メチルイミダゾリウム（［Ｃ４ｍｉｍ］＋）及び1-ヘキシル-3-メチルイミダゾリウム（［Ｃ６ｍｉｍ］＋）からなる群から選ばれる少なくとも１種を含む、イオン液体又は柔粘性結晶を提供するものである。

Fluoride ion battery electrolyte compositions

A fluoride ion battery includes a substantially lithium-free anode and cathode. At least one of the anode or cathode contains fluorine, and a substantially lithium-free liquid electrolyte is used for charge transport. The electrolyte is liquid at temperatures below about 200 degrees Celsius, and can be formed from an organic-soluble fluoride salt dissolved in selected classes of solvents.

Fluoride ion battery electrolyte compositions

A fluoride ion battery includes a substantially lithium-free anode and cathode. At least one of the anode or cathode contains fluorine, and a substantially lithium-free liquid electrolyte is used for charge transport. The electrolyte is liquid at temperatures below about 200 degrees Celsius, and can be formed from an organic-soluble fluoride salt dissolved in selected classes of solvents.

离子液体及柔粘性结晶

本发明提供一种离子液体或柔粘性结晶，其为由阴离子和阳离子构成的离子液体或柔粘性结晶，其中，阴离子含有[C(SO 2 F) 3 ] ‑ ，阳离子含有选自由1‑乙基‑3‑甲基咪唑鎓([EMI] + )、N,N‑二乙基‑N‑甲基‑(2‑甲氧基乙基)铵([DEME] + )、N‑甲基‑N‑丙基吡咯烷鎓([Py 13 ] + )、N‑甲基‑N‑丙基哌啶鎓([PP 13 ] + )、四甲基铵([N 1111 ] + )、四乙基铵([N 2222 ] + )、三甲基己基铵([N 6111 ] + )、三乙基己基铵([N 6222 ] + )、N‑甲基‑N‑乙基吡咯烷鎓([Py 12 ] + )、1‑丁基‑3‑甲基咪唑鎓([C 4 mim] + )及1‑己基‑3‑甲基咪唑鎓([C 6 mim] + )构成的组中的至少1种。

Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas

La presente solicitud se refiere a un procedimiento novedoso y eficiente para preparar nuevas 5-fluoro-1H-pirazolopiridinas sustituidas de la fórmula (VI) que son adecuadas como un intermedio para producción de medicamentos y para producción de medicamentos para el tratamiento y/o la profilaxis de trastornos cardiovasculares. Más particularmente, las 5-fluoro-1H-pirazolopiridinas de la fórmula (VI) son adecuadas para la preparación del compuesto de la fórmula (I) que sirve para producción de medicamentos, para producción de medicamentos para el tratamiento y/o la profilaxis de trastornos cardiovasculares.

Молекулярное сито emm-23, его синтез и применение

Изобретение относится к синтезу цеолитных молекулярных сит. Описано новое молекулярное сито, обозначенное как ЕММ-23. В прокаленной форме полученный продукт обладает рентгенограммой, включающей пики, указанные в таблице 1: Таблица 1 Межплоскостное расстояние (Å) Относительная интенсивность [100×I/I(o)] 17,5-16,3 60-100 10,6-10,1 5-50 9,99-9,56 20-70 6,23-6,06 1-10 5,84-5,69 1-10 5,54-5,40 1-10 4,29-4,21 1-10 3,932-3,864 1-10 3,766-3,704 5-40 3,735-3,674 1-10 3,657-3,598 1-10 3,595-3,539 1-20 Синтезированный продукт рекомендован в качестве эффективного катализатора превращений органических соединений и адсорбента. 6 н. и 9 з.п. ф-лы, 3 ил., 7 табл., 10 пр. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК C01B 39/48 (13) 2 599 745 C2 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2014104675/05, 24.07.2012 (24) Дата начала отсчета срока действия патента: 24.07.2012 Приоритет(ы): (30) Конвенционный приоритет: (72) Автор(ы): БЕРТОН Аллен У. (US), СТРОМАЙЕР Карл Г. (US), ВРОМАН Хилда Б. (US) 04.08.2011 US 61/514,939; 19.09.2011 EP 11181734.2 R U (73) Патентообладатель(и): ЭКСОНМОБИЛ КЕМИКЭЛ ПЕЙТЕНТС ИНК. (US) (43) Дата публикации заявки: 10.09.2015 Бюл. № 25 2 5 9 9 7 4 5 (45) Опубликовано: 10.10.2016 Бюл. № 28 (56) Список документов, цитированных в отчете о поиске: US 2002/0081262 A1 27.06.2002. US 2008/0292543 A1 27.11.2008. US 6136290 A 24.10.2000. US 5192521 A 09.03.1993. EA 10793 B1 30.12.2008. RU 2328445 C2 10.07.2008. (85) Дата начала рассмотрения заявки PCT на национальной фазе: 04.03.2014 US 2012/047910 (24.07.2012) C 2 C 2 (86) Заявка PCT: (87) Публикация заявки PCT: R U 2 5 9 9 7 4 5 WO 2013/019462 (07.02.2013) Адрес для переписки: 105082, Москва, Спартаковский пер., д. 2, стр. 1, секция 1, этаж 3, "ЕВРОМАРКПАТ" (54) МОЛЕКУЛЯРНОЕ СИТО EMM-23, ЕГО СИНТЕЗ И ПРИМЕНЕНИЕ (57) Реферат: 6,23-6,06 1-10 Изобретение относится к синтезу цеолитных 5,84-5,69 1-10 молекулярных сит. Описано новое молекулярное 5,54 ...

Method for producing substituted 5-fluoro-1h-pyrazolopyridines

본 출원은 의약을 제조하기 위한 중간체 및 심혈관 장애의 치료 및/또는 예방용 의약을 제조하기 위한 중간체로서 적합한 하기 화학식 VI의 신규 치환된 5-플루오로-1H-피라졸로피리딘을 제조하는 신규하고 효율적인 방법에 관한 것이다. 특히, 하기 화학식 VI의 5-플루오로-1H-피라졸로피리딘은 의약의 제조, 심혈관 장애의 치료 및/또는 예방용 의약의 제조에 사용되는 하기 화학식 I의 화합물의 제조에 적합하다. <화학식 VI> <화학식 I>

Quinuclidinol derivatives as antagonists of muscarinic receptors

1. Соединение формулы (I) !! где R1 представляет собой C1-6алкил; ! R2 представляет собой фенильное или 5-6-членное гетероарильное кольцо, каждое из которых возможно может быть замещено одним или более заместителями, независимо выбранными из галогена, циано, нитро, SH, S(O)0-2R10, NR11R12, S(O)2NR13R14, C(O)NR15R16, C(O)2R17, NR18S(O)2R19, NR20C(O)R21, NR22C(O)2R23, NR24C(O)NR25R26, OR27 и C1-6алкила, где C1-6алкил возможно может быть замещен одним или более заместителями, независимо выбранными из галогена, гидроксила, C1-6алкокси, NH2, группы NH(С1-6алкил) и группы N(С1-6алкил)2; ! R3 и R4 вместе с атомом азота, к которому они оба присоединены, образуют 4-8-членное алифатическое гетероциклическое кольцо, которое возможно может содержать дополнительный гетероатом, выбранный из кислорода, серы и азота, и которое возможно может быть замещено одним или более заместителями, независимо выбранными из галогена, гидроксила, C1-6алкокси и С1-6алкила, где C1-6алкил возможно может быть замещен одним или более заместителями, независимо выбранными из галогена и гидроксила; ! R5 представляет собой группу формулы (II) или (III) ! или ! где Y представляет собой -СН2-, -СН2СН2- или -СН2СН2СН2-, и кольцо в группе (II) замещено по 3 или 4 положениям; ! а равен 1 или 2; ! b равен 1 или 2; ! Z представляет собой -СН2-; ! R6 представляет собой группу формулы (IV) ! ! где w равен 0 или 1; ! R7 представляет собой С1-4алкилен, возможно замещенный одним или более заместителями, независимо выбранными из галогена, гидроксила, C1-6алкокси, NH2, группы NH(С1-6алкил) и группы N(С1-6алкил)2, ! когда w равен 0, тогда у равен 0; когда w равен 1, тогда у равен 0 или 1; ! Q представляет собой О, С(O), S(O)0-2, NR9, -CONR9-, -SO2NR9-, -NR9CO-, -NR9SO2-, -OC(O)-, -C(O)O-, -HC=CH- или этинилен; ! R8 представляет собой циклич� (19) РОССИЙСКАЯ ФЕДЕРАЦИЯ RU (11) 2009 120 229 (13) A (51) МПК A61K 31/439 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ЗАЯВКА НА ...

Water-soluble composition, the manufacturing method of its solidfied material and its solidfied material and acyl group phosphinates

提供：保存稳定性优异、能适应于宽范围的光源、能形成高精细的图案的水溶性组合物、其固化物的制造方法及其固化物、以及酰基次膦酸盐。含有：下述通式(I)(式中，X 1 表示碳原子数6～15的芳基，X 2 表示碳原子数1～8的直链的烷基等，A m+ 表示碱金属离子等，m表示1～3的数。)所示的酰基次膦酸盐(A)、具有下述通式(II)(式中，R 1 表示氢原子等，Z 1 表示氧原子等，R 2 表示氢原子等，Z 2 表示碳原子数1～6的亚烷基，n表示0～30的数，*是指结合键，具有多个通式(II)所示的基团的情况下，多个存在的R 1 、X 1 、X 2 、n任选分别相同或不同。)所示的基团的化合物(B)。

Emm-23 molecular sieve material, its synthesis and use

The novel molecular sieve material is named EMM-23, which has an X-ray diffraction pattern comprising the peaks of the following Table 1 in its as-calcined form: [Table 1]

Quaternary ammonium phosphate compound and preparation process thereof

PURPOSE: A quaternary ammonium phosphate compound is provided which is corrosion inhibitive on various metals including corrosive metals such as carbon steel, cast iron, stainless steel, copper, tin plated steel sheet and aluminum by having strong corrosion proofing and sterilization properties, and a preparation process thereof is also provided. CONSTITUTION: The quaternary ammonium phosphate compound is represented as in the following formula 1a and has corrosion proofing and sterilization effects at the same time. In formula 1a, R1 is para-(α,α,γ,γ)-tetramethyl butyl phenoxy ethoxy ethyl group, and R2 and R3 are methyl group. The preparation process of the quaternary ammonium phosphate compound represented as in the following formula 1 comprises the step of reacting quaternary ammonium hydroxide represented as in the following formula 3 with orthophosphates in a solvent containing alcohol with carbon atoms of 1 to 4. In formula 3 and formula 1, R1, as a linear or branched alkyl(or aryl) radical with 1 to 27 carbon atoms without containing hydroxyl group, can contain hetero atoms, and R2 and R3, as a methyl group, are the same as each other, or combined each other to form a hetero ring compound with 4 to 6 carbon atoms comprising oxygen and nitrogen.

Use of ionic liquids with tetracyanoborate anions as solvent for extraction of alcohols from aqueous solutions

FIELD: chemistry. SUBSTANCE: present invention relates to a method for liquid-liquid extraction of alcohols from aqueous solutions using at least one ionic liquid containing a tetracyanoborate anion as a solvent, as well as use of at least one ionic liquid containing a tetracyanoborate anion for extraction of alcohols from aqueous solutions. EFFECT: invention is aimed at providing novel extractants for liquid-liquid extraction of alcohols from aqueous solutions. 15 cl, 13 ex, 7 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 492 161 (13) C2 (51) МПК C07C C07C C07C B01D C01B 31/00 31/12 29/84 11/04 35/12 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2010152751/04, 15.05.2009 (24) Дата начала отсчета срока действия патента: 15.05.2009 (73) Патентообладатель(и): МЕРК ПАТЕНТ ГМБХ (DE) R U Приоритет(ы): (30) Конвенционный приоритет: 26.05.2008 EP 08009552.4 09.09.2008 EP 08015819.9 (72) Автор(ы): ПИТНЕР Уилльям-Роберт (DE), ШУЛЬТЕ Михаэль (DE), ГОРАК Анджей (DE), САНТАНДЖЕЛО Франческа (DE), ВЕНТИНК Аннебарт Энгберт (DE) (43) Дата публикации заявки: 10.07.2012 Бюл. № 19 2 4 9 2 1 6 1 (56) Список документов, цитированных в отчете о поиске: P. Izak et al. Increased productivity of Clostridium acetobutylicum fermentation of acetone, butanol, and ethanol by pervaporation through supported ionic liquid membrane// Applied Microbiology and Biotechnology. - 2008, 78(4), 597-602. WO 2008022233 A1, 21.02.2008. A. Chapeaux et al. Liquid Phase Behavior of Ionic Liquids with Water and 1-Octanol (см. прод.) C 2 C 2 (45) Опубликовано: 10.09.2013 Бюл. № 25 R U 2 4 9 2 1 6 1 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 27.12.2010 (86) Заявка PCT: EP 2009/003485 (15.05.2009) (87) Публикация заявки РСТ: WO 2009/152906 (23.12.2009) Адрес для переписки: 105082, Москва, Спартаковский пер., д. 2, стр. 1, секция 1, этаж 3, "Евромаркпат" (54) ПРИМЕНЕНИЕ ИОННЫХ ЖИДКОСТЕЙ С ...

Preparation method of bifluorosulfonyl imide onium salt

本发明涉及一种双氟磺酰亚胺鎓盐的制备方法，通过采用氟化氢作为氟化试剂和反应溶剂与双氯磺酰亚胺、鎓离子卤化物反应制得双氟磺酰亚胺鎓盐，从而达到降低原料成本，减少物料消耗和废弃物生成，提高原料利用率、产品收率和纯度，并使产品的纯化更容易，制备工艺流程更简洁高效，为大规模产业化制备双氟磺酰亚胺鎓属盐打下良好的技术基础。

Process for the preparation of an N-methyl-substituted triacetoneamine compound

Die vorliegende Erfindung beschreibt ein Verfahren zur Herstellung einer N-methylsubstituierten Triacetonaminverbindung. The present invention describes a process for preparing an N-methyl-substituted triacetoneamine compound.

Polycationic amphiphiles and polymers thereof as antimicrobial agents and methods using same

The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes novel polymers of polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and/or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and/or biofilm-embedded microorganisms on a surface.

Method for the production of onium salts with tetrafluoroborate anion having a reduced halide content

Cyclic quaternary ammonium salts as additives to fuel or lubricants

FIELD: fuel industry.SUBSTANCE: invention relates to a method of producing a diesel fuel composition, comprising obtaining a quaternary ammonium compound by reacting (a) a cyclic tertiary amine, containing less than 19 carbon atoms, which is an N-alkyl-heterocycle selected from pyrrolidine, piperidine, morpholine, piperazine, pyrrole, imidazole and dihydropyrrol, with (b) epoxide, selected from ethylene oxide, propylene oxide, butylene oxide, pentylene oxide, hexylene oxide, heptylene oxide and glycidyl ethers, in the presence of (c) carboxylic acid of formula R5COOH, where R5is CHR11CHR12COOR13, where one of R11and R12is hydrogen and the other is a polyisobutenyl group or an optionally substituted alkyl or alkenyl group, having 6 to 50 carbon atoms, and R13is hydrogen or an optionally substituted alkyl group; and mixing quaternary ammonium compound with fuel.EFFECT: technical result is obtaining a new composition which improves operational characteristics of a diesel engine.14 cl, 2 tbl, 8 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 737 162 C2 (51) МПК C07D 207/04 (2006.01) C07D 295/04 (2006.01) C07D 231/10 (2006.01) C10L 1/232 (2006.01) C10L 10/18 (2006.01) C10M 133/38 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07D 207/04 (2020.02); C07D 295/04 (2020.02); C07D 231/10 (2020.02); C10L 1/232 (2020.02); C10L 10/18 (2020.02); C10M 133/38 (2020.02) (21)(22) Заявка: 2018104097, 28.07.2016 28.07.2016 (73) Патентообладатель(и): ИННОСПЕК ЛИМИТЕД (GB) Дата регистрации: 25.11.2020 28.07.2015 GB 1513304.4 (43) Дата публикации заявки: 28.08.2019 Бюл. № 25 (45) Опубликовано: 25.11.2020 Бюл. № 33 (86) Заявка PCT: GB 2016/052312 (28.07.2016) C 2 C 2 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 28.02.2018 (87) Публикация заявки PCT: 2 7 3 7 1 6 2 WO 2017/017454 (02.02.2017) R U 2 7 3 7 1 6 2 Приоритет(ы): (30) Конвенционный приоритет: (56) Список документов, цитированных в отчете о поиске: US 2013/ ...

Method for producing quaternary ammonium compounds

The inventive method for producing quaternary ammonium compounds consists in reacting compounds containing an sp3 hybridised nitrogen atom with dialkyl sulphate or trialkyl phosphate and in exposing the thus obtained ammonium compound to an ion-exchange.

Method for preparing quaternary ammonium salt ionic liquid without halogen ions and sodium ions

本发明提供一种不含卤素离子和钠离子的季铵盐离子液体的制备方法，包括以下步骤：1)将叔胺溶解于非极性有机溶剂中与硫酸二烷基酯进行反应，得到硫酸单烷基酯季铵盐离子液体，静置分层后将下层液体用非极性有机溶剂洗涤3～5次，于真空条件下进行薄膜蒸发，去除残留的有机溶剂，得到半成品；2)将步骤1)得到的半成品和盐溶解于去离子水中进行盐交换反应，得到季铵盐离子液体，静置分层后将下层的油状液体用去离子水洗涤3～5次，薄膜蒸发纯化，去除残留水分，得到不含卤素离子和钠离子的季铵盐离子液体成品。本发明制备出的季铵盐离子液体纯度可达99.9％以上，并且其中不含有卤素离子和金属钠离子，可满足锂电池电解液和超级电容电解质的要求。

Method for producing quaternary ammonium compounds

The present invention relates to a process for preparing quaternary ammonium compounds, which comprises reacting compounds comprising an sp 3 -hybridized nitrogen atom with a dialkyl sulfate or trialkyl phosphate and subjecting the resulting ammonium compound to an anion exchange.

Method for producing triarylorganoborates

Provided herein is a process for preparing triaryl organoborates of the formula 1/n K n+ R 3 4 B − —R 1 (IV), where one equivalent of organoboronic ester of the formula B—R 1 (OR 2 )(OR 3 ) (I) is initially charged together with 1/n equivalents of salt K n+ nX − (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1, 3 equivalents of a haloaromatic R 4 —Y (III) are added, an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n K n+ R 3 4 B − —R 1 (IV) is separated off with the organic phase, and to the use of these substances as co-initiator in photopolymer formulations.

COSMETIC METHOD FOR LIGHTENING THE SKIN WITH ANIONIC OPTICAL AZURANT

L'invention concerne un procédé cosmétique d'éclaircissement et/ou de blanchiment de la peau comprenant l'application topique d'une composition comprenant un azurant optique neutralisé par un sel d'ammonium, et un procédé de maquillage et/ou de soin à l'aide d'une telle composition cosmétique L'invention a pour objet l'utilisation d'un azurant optique anionique d'un cation ammonium comme agent éclaircissant. The invention relates to a cosmetic process for lightening and / or bleaching the skin, comprising the topical application of a composition comprising an optical brightener neutralized with an ammonium salt, and a process for making and / or caring for The invention relates to the use of an anionic optical brightener of an ammonium cation as lightening agent.

TINCTORIAL COMPOSITION COMPRISING CATIONIC META-PHENYLENEDIAMINE

L'invention a pour objet un composé méta-phénylènediamine de formule (I) suivante, ses sels d'addition avec un acide et ses solvates : dans laquelle: . R représente un atome d'hydrogène ou d'halogène ; un radical alkyle en C1-C4 ; un radical carboxyle ; un radical alcoxy(C1-C4)carbonyle, . R1 représente un radical (hydroxy)alkyle C1- C10 éventuellement interrompu par un ou plusieurs atomes d'oxygène non adjacents ou groupements NR' non adjacents, substitué par un radical cationique CAT, . R2 représente un atome d'hydrogène ou un radical (hydroxy)alkyle C1- C4. . R1 et R2 peuvent former ensemble avec l'atome qui les porte un hétérocycle cationique de 5 à 8 chainons. . R' représente un atome d'hydrogène ou un radical (hydroxy)alkyle C1-C4; . An- représente un anion ou un mélange d'anions, organiques ou minéraux, cosmétiquement acceptables. The subject of the invention is a meta-phenylenediamine compound of formula (I) below, its addition salts with an acid and its solvates: in which: R represents a hydrogen or halogen atom; a C1-C4 alkyl radical; a carboxyl radical; a (C1-C4) alkoxycarbonyl radical, R1 represents a C1-C10 (hydroxy) alkyl radical optionally interrupted by one or more non-adjacent oxygen atoms or non-adjacent NR 'groups, substituted by a cationic radical CAT, R2 represents a hydrogen atom or a (hydroxy) C1-C4 alkyl radical. . R1 and R2 together with the atom carrying them can form a cationic heterocycle of 5 to 8 members. . R 'represents a hydrogen atom or a (hydroxy) C1-C4 alkyl radical; . An- represents an anion or a mixture of anions, organic or inorganic, cosmetically acceptable.

COSMETIC METHOD FOR LIGHTENING THE SKIN WITH ANIONIC OPTICAL AZURANT

L'invention concerne un procédé cosmétique d'éclaircissement et/ou de blanchiment de la peau comprenant l'application topique d'une composition comprenant un azurant optique neutralisé par un sel d'ammonium, et un procédé de maquillage et/ou de soin à l'aide d'une telle composition cosmétique L'invention a pour objet l'utilisation d'un azurant optique anionique d'un cation ammonium comme agent éclaircissant. The invention relates to a cosmetic process for lightening and / or bleaching the skin, comprising the topical application of a composition comprising an optical brightener neutralized with an ammonium salt, and a process for making and / or caring for The invention relates to the use of an anionic optical brightener of an ammonium cation as lightening agent.

TINCTORIAL COMPOSITION COMPRISING CATIONIC META-PHENYLENEDIAMINE

Process for preparing water soluble theophylline compounds

Substituted 5-fluoro-1h-pyrazolopyridines in crystalline form

SALT OF PENTACYLIC ANION AND ITS USE AS ELECTROLYTE

Method for producing substituted 5-fluoro-1h-pyrazolopyridines

The disclosure relates to a method for producing an aldehyde of the formula (III) which are further used in the preparation of substituted 5-fluoro-1H-pyrazolopyridines. The substituted 5-fluoro-1H-pyrazolopyridines are suitable as an intermediate for producing medicaments, in particular medicaments for the treatment and/or prophylaxis of cardiovascular disorders.

Method for producing triarylorganoborates

The invention relates to a method for producing triarylorganoborates from organoboronic acid esters in the presence of an n-valent cation 1/n K n+ , comprising the anhydrous treatment of the reaction mixture, and to the use of the obtained triarylorganoborates as coinitiators in photopolymer formulations, holographic media and holograms. The claimed method includes providing an alkyl or cycloalkylboronic acid ester of formula B-R'(OR2)(OR3) in an aprotic solvent in the presence of a metal, adding the aryl halide to produce an organometallic compound in situ, adding a ligand for the ion exchange and separation of the produced metal salts and solids (formula (A)). Triarylalkylborates of formulas (C) and (CC) are also claimed.

Plant growth regulator compositions

The invention provides novel mepiquat plant growth regulator compositions which have improved hygroscopicity and corrosion characteristics. The novel mepiquat plant growth regulator compositions of the invention can be readily prepared from technical mepiquat chlorid inter alia by electrochemical ion exchange processes or by quaternization of N-methylpiperidine with dimethylcarbonate as starting material.

Method for producing substituted 5-fluoro-1h-pyrazolopyridines

The present application relates to a novel and efficient method for producing novel substituted 5-fluoro-lH-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for producing medicaments and for producing medicaments for the treatment and/or prophylaxis of cardiovascular disorders. In particular, the 5-fluoro-lH-pyrazolopyridines of the formula (VI) are suitable for producing the compound of the formula (I) which serves for producing medicaments, for producing medicaments for the treatment and/or prophylaxis of cardiovascular disorders.

Quaternary morpholinium phosphites

Quaternary ammonium perfluoroalkoxy salts in the preparation of perfluoropolyethers

Quaternary ammonium picolinates - with hypotensive, ganglioplegic and antiseptic activity

Quaternary ammonium picolinates are of formula (I) (where X, X1-3 are 1-20C hydrocarbyl opt. substd. by a halo, CN, OH; 9C acyl, 9C acyloxy or 9C hydroacyloxy; or 2 or 3 of X,X1-3 may be linked to one another directly or via an O-atom to form a heterocyclic ring with the N-atom; R is H, alkyl, alkenyl, cycloalkyl, phenyl, halophenyl, alkylphenyl, or alkoxyphenyl). (I) are hypotensive, ganglioplegic and antiseptic agents.

Method for compressing a gaseous, oxygen-containing medium, comprises condensing the medium by means of a liquid piston containing ionic liquid

Es wird ein Verfahren zum Verdichten eines gasförmigen, Sauerstoff-enthaltenden Mediums, vorzugsweise von Sauerstoff, wobei die Verdichtung mittels eines Flüssigkeitskolbens erfolgt, sowie eine Betriebsflüssigkeit für einen Sauerstoffverdichter, in dem die Verdichtung mittels eines Flüssigkeitskolbens erfolgt, beschrieben. Erfindungsgemäß ist die Betriebsflüssigkeit eine ionische Flüssigkeit oder ein Gemisch aus zwei oder mehr unterschiedlichen ionischen Flüssigkeiten.

Processes for preraring aldehydes

The application relates to a process for preparing aldehydes of the formula (III)which are suitable as an intermediate for producing medicaments and for producing medicaments for the treatment and/or prophylaxis of cardiovascular disorders.

Quaternary ammonium antiarrhythmic drugs

Abstract Novel quaternary ammonium salts of certain phenylpropylamines and phenylbutylamines are dis-closed. They are useful drugs for treating arrhythmia and prolonging the action potential of cardiac muscle. They are prepared by reacting a tertiary amine with an alkyl salt.

Pentacyclic anion salt and use thereof as an electrolyte

Ionic liquid and plastic crystal

The present invention provides an ionic liquid or plastic crystal comprising an anion and a cation, the anion comprising [C(SO 2 F) 3 ] - , and the cation comprising at least one member selected from the group consisting of 1-ethyl-3-methylimidazolium ([EMI] + ), N,N-diethyl-N-methyl-(2-methoxyethyl)ammonium ([DEME] + ), N-methyl-N-propylpyrrolidinium ([PY 13 ] + ), N-methyl-N-propylpiperidinium ([PP 13 ] + ), tetramethylammonium ([N 1111 ] + ), tetraethylammonium ([N 2222 ] + ), trimethylhexylammonium ([N 6111 ] + ), triethylhexylammonium ([N 6222 ] + ), N-methyl-N-ethylpyrrolidinium ([Py 12 ] + ), 1-butyl-3-methylimidazolium ([C 4 mim] + ), and 1-hexyl-3-methylimidazolium ([C 6 mim] + ).

A purification method of ionic liquids to obtain their high purity

발명은 액체/액체 연속 추출을 이용하여 미정제 이온성 액체로부터 유기 할라이드 염, 유기염, 잔류 할라이드, 잔류 산, 과량의 알칼리 금속 등의 제거하여 유기, 무기 및 생화학 반응에서 용매로 사용할 수 있으며 축전지, 2차 전지. 연료전지의 전해액으로 사용 가능한 고순도의 이온성 액체를 제조하기 위한 이온성 액체의 정제방법에 관한 것이다. The invention utilizes liquid / liquid continuous extraction to remove organic halide salts, organic salts, residual halides, residual acids, excess alkali metals, etc. from crude ionic liquids and can be used as solvents in organic, inorganic and biochemical reactions , Secondary battery. The present invention relates to a method for purifying an ionic liquid for producing a high purity ionic liquid that can be used as an electrolyte of a fuel cell.

A kind of ionic liquid and its preparation method and application containing amino acid of the cation with amino

本发明涉及一种阳离子带氨基的含有氨基酸的离子液体及其制备方法和应用。所述的带有氨基酸的离子液体中，阴离子为氨基酸，阳离子为带有氨基的阳离子。本发明提供的含有氨基酸的功能化离子液体，该离子液体在催化二氧化碳与环氧化合物合成环状碳酸酯中，具有产量高，活性强，无需助催化剂和其他溶剂，反应条件温和，稳定性高且对环境无污染、绿色环保等优点。

Ionic liquid and plastic crystal

Preparation of fluorosulfonate onium salts

Synthesis of hetero ionic compounds using dialkylcarbonate quaternization

Methods of preparing hetero ionic complexes, and ionic liquids from bisulfate salts of heteroatomic compounds using dialkylcarbonates as a primary quaternizing reactant are disclosed. Also disclosed are methods of making electrochemical cells comprising the ionic liquids, and an electrochemical cell comprising an alkaline electrolyte and a hetero ionic complex additive.

Preparation of fluorosulfonic acid ester and onium salt derived thereform

Use of an ionic liquid for storing hydrogen

Method of storing hydrogen by forming a first ionic liquid by inducing a borohydride in a second ionic liquid comprising a cation and an anion comprising borate, and forming the second ionic liquid by releasing the hydrogen out of the first ionic liquid by using water and/or a catalyst, which method is characterized in that the first and the second ionic liquid are both water miscible and the second ionic liquid is separated, particularly is salted out, from solution in water by adding a separation inducer; certain ionic liquids for storing and releasing hydrogen comprising a borohydride or for preparing a ionic liquid for storing and releasing hydrogen comprising a borate; and a process for preparing ionic liquids for storing and releasing hydrogen comprising a borohydride.

Synthesis of hetero ionic compounds using dialkylcarbonate quaternization

Methods of preparing hetero ionic complexes, and ionic liquids from bisulfate salts of heteroatomic compounds using dialkylcarbonates as a primary quaternizing reactant are disclosed. Also disclosed are methods of making electrochemical cells comprising the ionic liquids, and an electrochemical cell comprising an alkaline electrolyte and a hetero ionic complex additive. - 1/2 -4 - ----- -- (N Fig. 1

ANALOGY PROCEDURE FOR PREPARING QUATERNARY AMMONIUM SALTS OF PHENYL BUTYLAMINES

Amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use

The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1 , 2 , 3 , 4 , 5 or 6 , and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.

Low melting point ionic liquids for infra-red liquid lens design

A liquid lens can include a lens body forming a cavity with a conducting liquid and an insulating liquid disposed therein, the conducting liquid substantially immiscible with the insulating liquid to define an interface between the conducting and insulating liquids. The conducting liquid can include an ionic compound of either a dicyanamide anion and a cation counterion, or a tricyanomethanide anion and a cation counterion, the dicyanamide anion having the formula the tricyanomethanide anion having the formula and the cation counterion is one of an imidazolium, a pyrrolidininium, a piperidinium, a phosphonium, a pyridinium, a pyrrolinium or a sulfonium cation. The ionic compound of the conducting liquid can be N-methyl-N-ethylpyrrolidinium dicyanamide, l-ethyl-3-methylimidazolium dicyanamide, 1-butyl-l-methylpyrrolidinium tricyanomethanide, or 1- ethyl-3-methylimidazolium tricyanomethanide, among others. The conducting liquid can have transmittance of at least 50% over a thickness of 1 mm for electromagnetic waves having wavelength of 1550 nm.

Cyclic quaternary ammonium salts as fuel or lubricant additives

Quaternary ammonium salts of formula: wherein each of R1 and R2 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms, R together with N forms an aliphatic or aromatic heterocycle having less than 12 carbons atoms and R5 is hydrogen or an optionally substituted hydrocarbyl group. The use of these compounds as fuel or lubricant additives, especially as diesel fuel additives.

Benethamine salt forms of atorvastatin